news/blog

corporate

English

_ga_HT7GV47KQ8

Domain 'peptidesexplorer.com' uses the commercial generic top-level domain (.com) without a subdomain. The second-level label 'peptidesexplorer' is 16 characters long split between six vowels and ten consonants. Segmentation suggests 2 words: peptides, explorer. Expect 8 characters per word on average. No strong language cues emerged from the frequency lists.

html/cc/3b/cc3b2987-4027-409e-9ebb-9746f090fea6.html.gz

inline; filename="5c285b27cdda1fe8-s.p.a62025f2.woff2"

inline; filename="turbopack-546b8461fe66f369.js"

default-src 'self'; img-src 'self' https: data: blob:; script-src 'self' 'unsafe-eval' 'unsafe-inline' https://www.googletagmanager.com https://googleads.g.doubleclick.net; style-src 'self' 'unsafe-inline'; connect-src 'self' https:; frame-src 'self' http: https:; frame-ancestors *;

inline; filename="when-will-retatrutide-be-available-banner.webp"

inline; filename="when-will-retatrutide-be-available-timeline.webp"

appId=cid-v1:a894a21c-0197-44e5-b203-3cbc01252c82

script-src 'none'; form-action 'none'; frame-src 'none'; report-uri https://csp.withgoogle.com/csp/scaffolding/ascnsrsggc:139:0

appId=cid-v1:a449a586-8786-487f-a449-dc1b282a2628

default-src 'self'; img-src 'self' https: data: blob:; script-src 'self' 'unsafe-eval' 'unsafe-inline'; style-src 'self' 'unsafe-inline'; connect-src 'self' https: https://gateway-us.umami.dev; frame-src 'self' http: https:; frame-ancestors 'self';

1fbbdf409376ee882b078197b9c9a4d448fa4f4a972e3c90681db3af7fd8cc9d

bbc0826384faf59b3d35a439a95f7787cd19280ee35469c84cd0b213bc306f11

f9f261b74f6e37ca1666648eefd5abb99b9b7ef6fdf0f3967019841d91b00884

7ecde0050c802288c3d0e9d37f798c8cea5f602badb27b74df20a80b4a423968

5e857ad51dbb1b758cecb4481c3c700114fa3d44078dbb42fd62bd22a10ce5a8

c15dab6c6267b061e532899f2775890e4d0963a8d2d0d9245d416423c3d4562f

1701f4d16e2dca5ad2a22d2e7a2ce2ffde371f8d1ef993de72d95425288dbedf

e9786b1305894e4119bb9811a816dac9cf576755596dd989ee15b455749fc35e

0ff6531e2e48d1df255a99759040109385129e43e1e2618ee8517ecf0ab438ba

c281a3c25a185225e7b9b563d5c00fb772f49e9cd89e87ef4180ceccfcb022f1

8cd63d1c6bb3efcf8b16a7fc697daaf2e6da9c17a17e2773ec20e53decd67bc2

b79022e54da6b4e1f4ad388fa5247c14665cd17bfc4ceba082e88c1fbc2c0fb6

011f4fe359ae6572fef88c4bb2f2dd83203d713dbd78ae9000015cce3d92a623

b3d8674cccb9ae23ac9793534c1251411288b6f9614bc8f884c1d9d67ee672f6

b854714e0ded82de0d59ad1c111b5caa56e8f070d3ee3be964843d4b918c606e

d9908246abfd79ed0cf8e24c5380ff874df530732bd0ecad64f4c1c811122043

708fb9112597317e43f5eafaa58947d4acacfff4d9b07acb1799a3ccdb57b79e

70a7775b253f2f982aee368f0f23e1c49718478402528af610b9f07d6423886f

a577e729012d6de5f6229e18fb93f5b42a5603fb31fb1846305826dc850fdd92

67a7c24fb9e917a0b3202f3301aed248462ac27c1ab6391b3ad4a7748b7a0b7f

fcfc1ec6fd7f7695790ffc4681c302814ab5dc29c2f917b72587a4444d8726d6

3626c979c4ba0a4cf9da657787a677bfa027941c103f3dc77249ec3b345c1c3e

9a40447d4abbc075d5d052d5d006205f4810cc5264981ab56b9eab28ef34cb8c

e851e1f4b5177c96a7f8f2ac835d376960ec06f9d8e5d080217013b5845585b0

70bf4d8aa99c22ee395e706f6957dbd3294eb135c433886e5da5ad7fca973514

d314fe6524df46baa651497616b64a91994c3826b8b0e53b9c5cd0661fb2ef7f

c0d4c94d3f52f1cf11966c287e13a855b7fee1876533cad283e205c930b58da2

3814cddd18b2095e01abb745a99e5ada90178e709c09879324c3b623f2d829ea

fe119d8daac7d7c82bd5c6c41c30f1b21970d514eaa19536afa22e68c1a3d355

3e6186c8158cf45e64425940b8e4f9701f4ead8001f311b0572856edd96c8ecf

ab60339bb44d691bef1fbf622953e55fe36e996921d5522f59029434030ae036

5cc22582a1cd19667291c53cd8673213b2ccdff211be53e26387a32f719db99f

621ccad705d7286f51aff03b619aff81fe75bc1e0d24cd25be53bbbd9568510a

c06f5e65526ef9cad6a589d13a70e3c8c9ba93431879544a8bf094650dca0ea3

7a42d4085167db00c3b27475642b630acedc9e8b601f2c85bafbeb01740070c1

80f341f93328da20efd962649a373acd29e6c01b8ced2298ad1d9da696e90ae5

ca1597a8a90a7a2787f92e46923c88ca0081b16b6586a8d085fc5183b9ffcad6

657f15398a0c6ebe17cecedc6abb9e34e87c97f91f1f18cb67e4b9669ea66d2d

ce680c8daa0c160a2c3299d2eb690ab2b29fa57c2153b2d81e179faa998af258

54f6111349c9d2be649edf8dab0b9944fc3747e857f9aaceed135da283668648

e3ab6032f7a2e96d525ff384e39332b3e8e2961c643c49286bb1bf4255e64ce0

944a094b0b8c5ff647290819be5280e74e5695d0d98f4af22f0cbd909de99893

d3bfda2351f7d4643d3efa41deebf77bfaf13fbac8abf266adab3919f994b588

b85cb5eefe3fcdd54bc18bfaa3b32e51eafeb1921b83b6e26e117783e44b5082

f089d667e3a13b6bd0291159d44e207c996b0fed97f78bd797e3549748318df4

a3d67211dfa9f39085637b7bd49455e56d24d9118d418dc24e2b2d70c431f2bc

d326559f6e085f04e452e673adc77dba4cfa14ebc81457a2dec454abc9cdde5b

fcebdd947e61995d1033951875460c300367cf77c030f028abdf6f14454468cd

744bc888031f67562d62ca2ab4a43e9d3e7bd9056b1e13db42feb7d0b80bc668

4817774477e33dc4a8702fe468ae1ba35dcf38bc8b190ab1f30ea9ea745b4932

4dd6d80f3bf90abc58457ac153344686053a85d15a8a1201578458a31dfcad1b

1e522112b27f5eda989400190cda15bfb770e519067a774a48d86fedec205f08

70b747e6216a344e48def66d2d906af6e63895e82c2c8a259bc48258d079af28

6799722aecabef444b777242deb89ee3963e3820e5e36682dd29994f60a43b94

2014def6a247bf0c4500c2c4b52408d58c68de78bc8eaacd28d8d936f6c57508

a494e96daad303230616640fc749804bd8e6400976a58483762fc1bc1f4a879b

fc0abf476e661d4c8e9c92447140e885eba5e61d4db72e2ccd6c8efb4911320d

56c6185b21a90e2a6395954b41b5a052954264de15c02052a044438c513376de

0822ec365329f8bcce022cff84ce1317bdf634f38c87a4026f6710d051473bec

1be35ab0285ae87ff4e109b7fd06281239ae192e83d30dd28645594c4f8931b9

5af75f2bf32e4835544bb36152abbbb4d212f3f6fca744f67cae04cd62d0e9ad

ce8bff5ce720e218d5f6b371f6396d28d278287354e1b207e7c55c293ecee6c0

e0455267b1858067812604b13a76127d63a3010a50bc31d43df91abfb94db3b7

28fcac260dd1d6fa9da90bac0fd14c6754b2af538cdbb6f69d65286da4a2bbf0

e0d5e446b2558b738d0cf0592e6d9814658a82007f7b770679785d29ae7c75b1

10f1911770a75ef3747c770db145afdf0148356e0c3d83dbf7a56da787fc12c7

882ec00c41055074a0c6c675f0182231ff6edb8b0a311410747ff95bc53d8a87

2fd1885f4db4259c51a688e7021d392e775a277c17b61dbe69df4c1c18f26032

9f7311a45c375c84860389aaa64be058c35032bf1eecc9bac110a2692987b34e

9c8821265766afcad4fa0fd2beafbf6d7a3344287c5a4d868e48da46825e95dd

e483a20a1e6a1d789c64fffbd0813e4f05e5a037dc4d45398ec083face4897c5

313716753a1510c5e6d053eda2e3fbdd20dc5973c66b1cd7b1f0355c05d3f86f

955f1eac2b4048137db3b014a8c2900c4883da1c5d829a38b40cfa9b1d94771d

6e5842f269cb3dcb0ad9460c40487db3989c990c2258a292b4476a813d872951

2018aad98adf86b6c149d3d89d8596a3592a55ede164e42ac829e771432c3cde

06c7d423a42e40e7945d21ff4e485ca1cf020b2f04b59d8b9bea7e9d8933bacc

b4beeea3a8f6397a870e74cda6f5264c7c3e5c57972463e89173ed79238884dc

8208561552382c5aa96079a1cd13601131cb77c1a4aff01e66ccef655c248dcd

2299ace4d41bccbc5d817d88c186ff40f52525b18d357466b08955ded6e513b2

64ad5520096886ec9fdfb62a400a2cdc6e3776f04fba01605fe9eab0010c074d

19cfd344e71439180cd65c006b493eaadb0a63c81de3b8ca69ca34611600124b

e32b8011cd5f554b44c9fa6f912d025cb7478b273c2e751356c39728a4cf6e3f

19ac40502ebee1a84eceb6a4ceae1382d1fbbe8a9899d0686b41246fc604a30b

2f0be88ad5042ffa7c4869a08770fe0ebdefaee6f9ef0fe05962397785991168

0170b6a50c0bd551a3c05dfe7d1a26ddde975b2b23478b9f0ae2c06676dc2695

846cd9484a4ea20168d5f923ef3610f690a5435cbcecc0736a91b5a8c39ade64

54ddd465fda364c2e7adeca422554498d96b98515389b88ec08ef00a71362443

Giblin et al., Diabetes, Obesity and Metabolism 2026

viewport

next-size-adjust

Retatrutide is expected to receive FDA approval in mid-2027 with pharmacy availability in late 2027. Full timeline and Phase 3 trial status.

description

author

peptides,peptide quiz,best peptide for muscle growth,BPC-157,semaglutide,tirzepatide,peptide calculator,peptide protocol

keywords

creator

robots

index, follow, max-video-preview:-1, max-image-preview:large, max-snippet:-1

googlebot

https://peptidesexplorer.com/blog/when-will-retatrutide-be-available

https://peptidesexplorer.com/images/blog/when-will-retatrutide-be-available-banner.webp

twitter:card

twitter:title

twitter:description

twitter:image

GoDaddy.com, LLC

PEPTIDESEXPLORER.COM

Microsoft Corporation

IPHostmaster IPHostmaster

Somesh Chaturmohta

Prachi Singh

Dawn Bedard

MSFT

Science-backed peptide guides, dosage calculators, and research tools. Expert protocols for BPC-157, semaglutide, tirzepatide, and 25+ peptides.

PeptidesExplorer

Independent educational publisher covering research peptides: dosing literature, safety data, and regulatory status.

Retatrutide Availability & Timeline

The most realistic estimate is late 2027 to early 2028. Eli Lilly needs to finish Phase 3 trials (mid-2026), submit a New Drug Application (late 2026), and wait for the FDA to review it (6 to 10 months). Best case with Priority Review is Q3 2027. Standard Review pushes availability to Q4 2027 or Q1 2028.

When will retatrutide be available at pharmacies?

No. As of March 2026, retatrutide has not been approved by the FDA or any other regulatory agency worldwide. It is in Phase 3 clinical trials under Eli Lilly's TRIUMPH program. No doctor can prescribe it and no pharmacy can legally fill it. The only legal access is through clinical trials or, in extreme cases, expanded access.

Is retatrutide FDA-approved?

In the Phase 3 TRIUMPH-4 trial, participants on the highest dose (12 mg) lost an average of 28.7% of their body weight over 68 weeks. That translates to roughly 71 pounds from a 249-pound starting weight. Participants were still losing weight when the trial ended, suggesting the final number could be higher with longer use.

How much weight can you lose on retatrutide?

Some vendors sell retatrutide labeled 'for research use only.' These products are not manufactured to pharmaceutical standards and are not regulated by the FDA. Testing of seized samples has found bacterial endotoxins, heavy metals, and purity levels below 90%. The FDA has issued dozens of warning letters to peptide vendors since 2024.

Can I buy retatrutide online right now?

Retatrutide targets three receptors (GLP-1, GIP, glucagon) and produced 28.7% weight loss. Tirzepatide targets two receptors (GLP-1, GIP) and produced 22.5% weight loss. Semaglutide targets one receptor (GLP-1) and produced 15% weight loss. More receptors means more weight loss but also more side effects. Tirzepatide and semaglutide are available now. Retatrutide is not.

How does retatrutide compare to tirzepatide and semaglutide?

Unknown, but expectations are mixed. Coverage for weight loss drugs remains inconsistent across insurers. Based on tirzepatide precedent, diabetes-related indications will likely receive better coverage than obesity indications. Eli Lilly will almost certainly offer a manufacturer savings card to reduce out-of-pocket costs, similar to the $25/month Zepbound card.

Will insurance cover retatrutide?

Side effect rates vary significantly by trial population. In TRIUMPH-4 (obesity + knee OA): nausea 43%, diarrhea 33%, dysesthesia 20.9%. In TRANSCEND-T2D-1 (type 2 diabetes): nausea 26.5%, diarrhea 22.8%, dysesthesia 4.4%. Heart rate increased by 4 to 7 beats per minute. Most side effects were mild to moderate and improved over time. See our retatrutide side effects guide for the full breakdown.

What are the main side effects of retatrutide?

No. US law only allows compounding of FDA-approved drugs. Since retatrutide has never been approved, compounding it is illegal. Even after eventual approval, compounding would only be permitted during a drug shortage. Eli Lilly is investing billions in manufacturing to prevent shortages like those that affected semaglutide and tirzepatide.

Can a compounding pharmacy make retatrutide?

Home

Blog

(self.__next_f=self.__next_f||[]).push([0])

self.__next_f.push([1,"1:\"$Sreact.fragment\"\n2:I[79520,[\"/_next/static/chunks/0c3b51bb8a314d61.js?dpl=dpl_DMMMHYSgR6X9cNt8V3qQHF34gugs\",\"/_next/static/chunks/84258240d5deba58.js?dpl=dpl_DMMMHYSgR6X9cNt8V3qQHF34gugs\"],\"\"]\n3:I[70119,[\"/_next/static/chunks/0c3b51bb8a314d61.js?dpl=dpl_DMMMHYSgR6X9cNt8V3qQHF34gugs\",\"/_next/static/chunks/84258240d5deba58.js?dpl=dpl_DMMMHYSgR6X9cNt8V3qQHF34gugs\"],\"default\"]\n4:I[39756,[\"/_next/static/chunks/ff1a16fafef87110.js?dpl=dpl_DMMMHYSgR6X9cNt8V3qQHF34gugs\",\"/_next/static/chunks/3f0598874f2f538c.js?dpl=dpl_DMMMHYSgR6X9cNt8V3qQHF34gugs\"],\"default\"]\n5:I[53536,[\"/_next/static/chunks/ff1a16fafef87110.js?dpl=dpl_DMMMHYSgR6X9cNt8V3qQHF34gugs\",\"/_next/static/chunks/3f0598874f2f538c.js?dpl=dpl_DMMMHYSgR6X9cNt8V3qQHF34gugs\"],\"default\"]\nf:I[68027,[],\"default\"]\n:HL[\"/_next/static/chunks/d68cceae62add0c0.css?dpl=dpl_DMMMHYSgR6X9cNt8V3qQHF34gugs\",\"style\"]\n:HL[\"/_next/static/media/5c285b27cdda1fe8-s.p.a62025f2.woff2\",\"font\",{\"crossOrigin\":\"\",\"type\":\"font/woff2\"}]\n"])

self.__next_f.push([1,"0:{\"P\":null,\"b\":\"0C0UJLY7XsaYWl5R3AoE2\",\"c\":[\"\",\"blog\",\"when-will-retatrutide-be-available\"],\"q\":\"\",\"i\":false,\"f\":[[[\"\",{\"children\":[\"blog\",{\"children\":[[\"slug\",\"when-will-retatrutide-be-available\",\"d\"],{\"children\":[\"__PAGE__\",{}]}]}]},\"$undefined\",\"$undefined\",true],[[\"$\",\"$1\",\"c\",{\"children\":[[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/chunks/d68cceae62add0c0.css?dpl=dpl_DMMMHYSgR6X9cNt8V3qQHF34gugs\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"$undefined\"}],[\"$\",\"script\",\"script-0\",{\"src\":\"/_next/static/chunks/0c3b51bb8a314d61.js?dpl=dpl_DMMMHYSgR6X9cNt8V3qQHF34gugs\",\"async\":true,\"nonce\":\"$undefined\"}],[\"$\",\"script\",\"script-1\",{\"src\":\"/_next/static/chunks/84258240d5deba58.js?dpl=dpl_DMMMHYSgR6X9cNt8V3qQHF34gugs\",\"async\":true,\"nonce\":\"$undefined\"}]],[\"$\",\"html\",null,{\"lang\":\"en\",\"className\":\"scroll-smooth\",\"children\":[[\"$\",\"head\",null,{\"children\":[[\"$\",\"script\",null,{\"type\":\"application/ld+json\",\"dangerouslySetInnerHTML\":{\"__html\":\"{\\\"@context\\\":\\\"https://schema.org\\\",\\\"@type\\\":\\\"WebSite\\\",\\\"name\\\":\\\"PeptidesExplorer\\\",\\\"alternateName\\\":\\\"Peptides Explorer\\\",\\\"url\\\":\\\"https://peptidesexplorer.com\\\",\\\"description\\\":\\\"Science-backed peptide guides, dosage calculators, and research tools. Expert protocols for BPC-157, semaglutide, tirzepatide, and 25+ peptides.\\\",\\\"potentialAction\\\":{\\\"@type\\\":\\\"SearchAction\\\",\\\"target\\\":{\\\"@type\\\":\\\"EntryPoint\\\",\\\"urlTemplate\\\":\\\"https://peptidesexplorer.com/blog?q={search_term_string}\\\"},\\\"query-input\\\":\\\"required name=search_term_string\\\"}}\"}}],[\"$\",\"script\",null,{\"type\":\"application/ld+json\",\"dangerouslySetInnerHTML\":{\"__html\":\"{\\\"@context\\\":\\\"https://schema.org\\\",\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"PeptidesExplorer\\\",\\\"url\\\":\\\"https://peptidesexplorer.com\\\",\\\"logo\\\":\\\"https://peptidesexplorer.com/logo.png\\\",\\\"description\\\":\\\"Independent educational publisher covering research peptides: dosing literature, safety data, and regulatory status.\\\",\\\"sameAs\\\":[],\\\"publishingPrinciples\\\":\\\"https://peptidesexplorer.com/editorial-policy\\\",\\\"contactPoint\\\":{\\\"@type\\\":\\\"ContactPoint\\\",\\\"contactType\\\":\\\"customer support\\\",\\\"url\\\":\\\"https://peptidesexplorer.com/contact\\\"}}\"}}]]}],[\"$\",\"body\",null,{\"className\":\"dm_sans_7c902a1b-module__SQElmG__className bg-white text-[#111] antialiased\",\"children\":[[[[\"$\",\"$L2\",null,{\"src\":\"https://www.googletagmanager.com/gtag/js?id=G-HT7GV47KQ8\",\"strategy\":\"afterInteractive\"}],[\"$\",\"$L2\",null,{\"id\":\"google-analytics\",\"strategy\":\"afterInteractive\",\"children\":\"\\n              window.dataLayer = window.dataLayer || [];\\n              function gtag(){dataLayer.push(arguments);}\\n              gtag('js', new Date());\\n              gtag('config', 'G-HT7GV47KQ8');\\n            \"}]],[\"$\",\"$L2\",null,{\"src\":\"https://cloud.umami.is/script.js\\n\",\"data-website-id\":\"874554a9-2b34-41fb-8467-fc9a21d79383\",\"strategy\":\"afterInteractive\"}],[\"$\",\"$L2\",null,{\"id\":\"microsoft-clarity\",\"strategy\":\"afterInteractive\",\"children\":\"\\n          (function(c,l,a,r,i,t,y){\\n            c[a]=c[a]||function(){(c[a].q=c[a].q||[]).push(arguments)};\\n            t=l.createElement(r);t.async=1;t.src=\\\"https://www.clarity.ms/tag/\\\"+i;\\n            y=l.getElementsByTagName(r)[0];y.parentNode.insertBefore(t,y);\\n          })(window, document, \\\"clarity\\\", \\\"script\\\", \\\"vqzaktompu\\\");\\n        \"}]],[\"$\",\"$L3\",null,{}],[\"$\",\"main\",null,{\"children\":[\"$\",\"$L4\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L5\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[[\"$\",\"title\",null,{\"children\":\"404: This page could not be found.\"}],[\"$\",\"div\",null,{\"style\":{\"fontFamily\":\"system-ui,\\\"Segoe UI\\\",Roboto,Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\"\",\"height\":\"100vh\",\"textAlign\":\"center\",\"display\":\"flex\",\"flexDirection\":\"column\",\"alignItems\":\"center\",\"justifyContent\":\"center\"},\"children\":[\"$\",\"div\",null,{\"children\":[[\"$\",\"style\",null,{\"dangerouslySetInnerHTML\":{\"__html\":\"body{color:#000;background:#fff;margin:0}.next-error-h1{border-right:1px solid rgba(0,0,0,.3)}@media (prefers-color-scheme:dark){body{color:#fff;background:#000}.next-error-h1{border-right:1px solid rgba(255,255,255,.3)}}\"}}],\"$L6\",\"$L7\"]}]}]],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]}],\"$L8\",\"$L9\",\"$La\"]}]]}]]}],{\"children\":[\"$Lb\",{\"children\":[\"$Lc\",{\"children\":[\"$Ld\",{},null,false,false]},null,false,false]},null,false,false]},null,false,false],\"$Le\",false]],\"m\":\"$undefined\",\"G\":[\"$f\",[]],\"S\":true}\n"])

self.__next_f.push([1,"10:I[22016,[\"/_next/static/chunks/0c3b51bb8a314d61.js?dpl=dpl_DMMMHYSgR6X9cNt8V3qQHF34gugs\",\"/_next/static/chunks/84258240d5deba58.js?dpl=dpl_DMMMHYSgR6X9cNt8V3qQHF34gugs\",\"/_next/static/chunks/7fe1272d30dfa3e2.js?dpl=dpl_DMMMHYSgR6X9cNt8V3qQHF34gugs\"],\"\"]\n14:I[7325,[\"/_next/static/chunks/0c3b51bb8a314d61.js?dpl=dpl_DMMMHYSgR6X9cNt8V3qQHF34gugs\",\"/_next/static/chunks/84258240d5deba58.js?dpl=dpl_DMMMHYSgR6X9cNt8V3qQHF34gugs\"],\"default\"]\n15:I[19369,[\"/_next/static/chunks/0c3b51bb8a314d61.js?dpl=dpl_DMMMHYSgR6X9cNt8V3qQHF34gugs\",\"/_next/static/chunks/84258240d5deba58.js?dpl=dpl_DMMMHYSgR6X9cNt8V3qQHF34gugs\"],\"default\"]\n17:I[97367,[\"/_next/static/chunks/ff1a16fafef87110.js?dpl=dpl_DMMMHYSgR6X9cNt8V3qQHF34gugs\",\"/_next/static/chunks/3f0598874f2f538c.js?dpl=dpl_DMMMHYSgR6X9cNt8V3qQHF34gugs\"],\"OutletBoundary\"]\n18:\"$Sreact.suspense\"\n1a:I[97367,[\"/_next/static/chunks/ff1a16fafef87110.js?dpl=dpl_DMMMHYSgR6X9cNt8V3qQHF34gugs\",\"/_next/static/chunks/3f0598874f2f538c.js?dpl=dpl_DMMMHYSgR6X9cNt8V3qQHF34gugs\"],\"ViewportBoundary\"]\n1c:I[97367,[\"/_next/static/chunks/ff1a16fafef87110.js?dpl=dpl_DMMMHYSgR6X9cNt8V3qQHF34gugs\",\"/_next/static/chunks/3f0598874f2f538c.js?dpl=dpl_DMMMHYSgR6X9cNt8V3qQHF34gugs\"],\"MetadataBoundary\"]\n6:[\"$\",\"h1\",null,{\"className\":\"next-error-h1\",\"style\":{\"display\":\"inline-block\",\"margin\":\"0 20px 0 0\",\"padding\":\"0 23px 0 0\",\"fontSize\":24,\"fontWeight\":500,\"verticalAlign\":\"top\",\"lineHeight\":\"49px\"},\"children\":404}]\n7:[\"$\",\"div\",null,{\"style\":{\"display\":\"inline-block\"},\"children\":[\"$\",\"h2\",null,{\"style\":{\"fontSize\":14,\"fontWeight\":400,\"lineHeight\":\"49px\",\"margin\":0},\"children\":\"This page could not be found.\"}]}]\n"])

self.__next_f.push([1,"8:[\"$\",\"footer\",null,{\"className\":\"bg-[#F8F8F8] border-t border-gray-200\",\"children\":[\"$\",\"div\",null,{\"className\":\"max-w-6xl mx-auto px-4 sm:px-6 lg:px-8 py-16\",\"children\":[[\"$\",\"div\",null,{\"className\":\"grid grid-cols-1 sm:grid-cols-2 md:grid-cols-5 gap-10\",\"children\":[[\"$\",\"div\",null,{\"className\":\"col-span-1 sm:col-span-2\",\"children\":[[\"$\",\"$L10\",null,{\"href\":\"/\",\"className\":\"flex items-center gap-2 mb-4\",\"children\":[\"$\",\"span\",null,{\"className\":\"font-bold text-xl text-[#111]\",\"children\":[\"Peptides\",[\"$\",\"span\",null,{\"className\":\"text-[#1526C9]\",\"children\":\"Explorer\"}]]}]}],[\"$\",\"p\",null,{\"className\":\"text-[#666] text-sm leading-relaxed max-w-sm\",\"children\":\"Science-backed peptide recommendations tailored to your goals. Take our free quiz and discover your personalized protocol.\"}],[\"$\",\"div\",null,{\"className\":\"mt-6 p-4 bg-white rounded-2xl border border-gray-200\",\"children\":[\"$\",\"p\",null,{\"className\":\"text-[#999] text-xs leading-relaxed\",\"children\":\"This content is for educational and informational purposes only. It is not intended as medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.\"}]}]]}],[\"$\",\"div\",null,{\"children\":[[\"$\",\"h3\",null,{\"className\":\"text-[#111] font-semibold mb-4 text-sm uppercase tracking-wider\",\"children\":\"Explore\"}],[\"$\",\"ul\",null,{\"className\":\"space-y-3\",\"children\":[[\"$\",\"li\",null,{\"children\":[\"$\",\"$L10\",null,{\"href\":\"/quiz\",\"className\":\"text-[#666] hover:text-[#1526C9] text-sm transition-colors\",\"children\":\"Peptide Quiz\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L10\",null,{\"href\":\"/blog\",\"className\":\"text-[#666] hover:text-[#1526C9] text-sm transition-colors\",\"children\":\"Blog\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L10\",null,{\"href\":\"/tools\",\"className\":\"text-[#666] hover:text-[#1526C9] text-sm transition-colors\",\"children\":\"Free Tools\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L10\",null,{\"href\":\"/peptides\",\"className\":\"text-[#666] hover:text-[#1526C9] text-sm transition-colors\",\"children\":\"All Peptides\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L10\",null,{\"href\":\"/about\",\"className\":\"text-[#666] hover:text-[#1526C9] text-sm transition-colors\",\"children\":\"About Us\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L10\",null,{\"href\":\"/editorial-policy\",\"className\":\"text-[#666] hover:text-[#1526C9] text-sm transition-colors\",\"children\":\"Editorial Policy\"}]}]]}]]}],[\"$\",\"div\",null,{\"children\":[[\"$\",\"h3\",null,{\"className\":\"text-[#111] font-semibold mb-4 text-sm uppercase tracking-wider\",\"children\":\"Peptides\"}],[\"$\",\"ul\",null,{\"className\":\"space-y-3\",\"children\":[[\"$\",\"li\",null,{\"children\":[\"$\",\"$L10\",null,{\"href\":\"/peptides/bpc-157\",\"className\":\"text-[#666] hover:text-[#1526C9] text-sm transition-colors\",\"children\":\"BPC-157\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L10\",null,{\"href\":\"/peptides/semaglutide\",\"className\":\"text-[#666] hover:text-[#1526C9] text-sm transition-colors\",\"children\":\"Semaglutide\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L10\",null,{\"href\":\"/peptides/tirzepatide\",\"className\":\"text-[#666] hover:text-[#1526C9] text-sm transition-colors\",\"children\":\"Tirzepatide\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L10\",null,{\"href\":\"/peptides/tb-500\",\"className\":\"text-[#666] hover:text-[#1526C9] text-sm transition-colors\",\"children\":\"TB-500\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L10\",null,{\"href\":\"/peptides/ipamorelin\",\"className\":\"text-[#666] hover:text-[#1526C9] text-sm transition-colors\",\"children\":\"Ipamorelin\"}]}]]}]]}],[\"$\",\"div\",null,{\"children\":[[\"$\",\"h3\",null,{\"className\":\"text-[#111] font-semibold mb-4 text-sm uppercase tracking-wider\",\"children\":\"Guides\"}],[\"$\",\"ul\",null,{\"className\":\"space-y-3\",\"children\":[[\"$\",\"li\",null,{\"children\":[\"$\",\"$L10\",null,{\"href\":\"/blog/getting-started-with-peptides\",\"className\":\"text-[#666] hover:text-[#1526C9] text-sm transition-colors\",\"children\":\"Getting Started with Peptides\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L10\",null,{\"href\":\"/blog/peptide-safety-guide\",\"className\":\"text-[#666] hover:text-[#1526C9] text-sm transition-colors\",\"children\":\"Peptide Safety Guide\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L10\",null,{\"href\":\"/blog/peptide-stacking-guide\",\"className\":\"text-[#666] hover:text-[#1526C9] text-sm transition-colors\",\"children\":\"Peptide Stacking Guide\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L10\",null,{\"href\":\"/blog/peptide-dosage-chart\",\"className\":\"text-[#666] hover:text-[#1526C9] text-sm transition-colors\",\"children\":\"Peptide Dosage Chart\"}]}],\"$L11\",\"$L12\"]}]]}]]}],\"$L13\"]}]}]\n"])

self.__next_f.push([1,"9:[\"$\",\"$L14\",null,{}]\na:[\"$\",\"$L15\",null,{}]\nb:[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L4\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L5\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}]\nc:[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L4\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L5\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}]\nd:[\"$\",\"$1\",\"c\",{\"children\":[\"$L16\",[[\"$\",\"script\",\"script-0\",{\"src\":\"/_next/static/chunks/7fe1272d30dfa3e2.js?dpl=dpl_DMMMHYSgR6X9cNt8V3qQHF34gugs\",\"async\":true,\"nonce\":\"$undefined\"}]],[\"$\",\"$L17\",null,{\"children\":[\"$\",\"$18\",null,{\"name\":\"Next.MetadataOutlet\",\"children\":\"$@19\"}]}]]}]\ne:[\"$\",\"$1\",\"h\",{\"children\":[null,[\"$\",\"$L1a\",null,{\"children\":\"$L1b\"}],[\"$\",\"div\",null,{\"hidden\":true,\"children\":[\"$\",\"$L1c\",null,{\"children\":[\"$\",\"$18\",null,{\"name\":\"Next.Metadata\",\"children\":\"$L1d\"}]}]}],[\"$\",\"meta\",null,{\"name\":\"next-size-adjust\",\"content\":\"\"}]]}]\n"])

self.__next_f.push([1,"11:[\"$\",\"li\",null,{\"children\":[\"$\",\"$L10\",null,{\"href\":\"/blog/peptide-injections-complete-guide\",\"className\":\"text-[#666] hover:text-[#1526C9] text-sm transition-colors\",\"children\":\"Peptide Injections Guide\"}]}]\n12:[\"$\",\"li\",null,{\"children\":[\"$\",\"$L10\",null,{\"href\":\"/blog/where-to-buy-peptides-2026\",\"className\":\"text-[#666] hover:text-[#1526C9] text-sm transition-colors\",\"children\":\"Where to Buy Peptides\"}]}]\n13:[\"$\",\"div\",null,{\"className\":\"border-t border-gray-200 mt-12 pt-8 flex flex-col md:flex-row justify-between items-center gap-4\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-[#999] text-xs\",\"children\":[\"© \",2026,\" PeptidesExplorer. All rights reserved.\"]}],[\"$\",\"div\",null,{\"className\":\"flex gap-6\",\"children\":[[\"$\",\"$L10\",null,{\"href\":\"/contact\",\"className\":\"text-[#999] hover:text-[#666] text-xs transition-colors\",\"children\":\"Contact\"}],[\"$\",\"$L10\",null,{\"href\":\"/privacy\",\"className\":\"text-[#999] hover:text-[#666] text-xs transition-colors\",\"children\":\"Privacy Policy\"}],[\"$\",\"$L10\",null,{\"href\":\"/terms\",\"className\":\"text-[#999] hover:text-[#666] text-xs transition-colors\",\"children\":\"Terms of Use\"}],[\"$\",\"$L10\",null,{\"href\":\"/disclaimer\",\"className\":\"text-[#999] hover:text-[#666] text-xs transition-colors\",\"children\":\"Medical Disclaimer\"}]]}]]}]\n"])

self.__next_f.push([1,"1e:I[47299,[\"/_next/static/chunks/0c3b51bb8a314d61.js?dpl=dpl_DMMMHYSgR6X9cNt8V3qQHF34gugs\",\"/_next/static/chunks/84258240d5deba58.js?dpl=dpl_DMMMHYSgR6X9cNt8V3qQHF34gugs\",\"/_next/static/chunks/7fe1272d30dfa3e2.js?dpl=dpl_DMMMHYSgR6X9cNt8V3qQHF34gugs\"],\"default\"]\n1f:Ted5,"])

self.__next_f.push([1,"{\"@context\":\"https://schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"When will retatrutide be available at pharmacies?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The most realistic estimate is late 2027 to early 2028. Eli Lilly needs to finish Phase 3 trials (mid-2026), submit a New Drug Application (late 2026), and wait for the FDA to review it (6 to 10 months). Best case with Priority Review is Q3 2027. Standard Review pushes availability to Q4 2027 or Q1 2028.\"}},{\"@type\":\"Question\",\"name\":\"Is retatrutide FDA-approved?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. As of March 2026, retatrutide has not been approved by the FDA or any other regulatory agency worldwide. It is in Phase 3 clinical trials under Eli Lilly's TRIUMPH program. No doctor can prescribe it and no pharmacy can legally fill it. The only legal access is through clinical trials or, in extreme cases, expanded access.\"}},{\"@type\":\"Question\",\"name\":\"How much weight can you lose on retatrutide?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"In the Phase 3 TRIUMPH-4 trial, participants on the highest dose (12 mg) lost an average of 28.7% of their body weight over 68 weeks. That translates to roughly 71 pounds from a 249-pound starting weight. Participants were still losing weight when the trial ended, suggesting the final number could be higher with longer use.\"}},{\"@type\":\"Question\",\"name\":\"Can I buy retatrutide online right now?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Some vendors sell retatrutide labeled 'for research use only.' These products are not manufactured to pharmaceutical standards and are not regulated by the FDA. Testing of seized samples has found bacterial endotoxins, heavy metals, and purity levels below 90%. The FDA has issued dozens of warning letters to peptide vendors since 2024.\"}},{\"@type\":\"Question\",\"name\":\"How does retatrutide compare to tirzepatide and semaglutide?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Retatrutide targets three receptors (GLP-1, GIP, glucagon) and produced 28.7% weight loss. Tirzepatide targets two receptors (GLP-1, GIP) and produced 22.5% weight loss. Semaglutide targets one receptor (GLP-1) and produced 15% weight loss. More receptors means more weight loss but also more side effects. Tirzepatide and semaglutide are available now. Retatrutide is not.\"}},{\"@type\":\"Question\",\"name\":\"Will insurance cover retatrutide?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Unknown, but expectations are mixed. Coverage for weight loss drugs remains inconsistent across insurers. Based on tirzepatide precedent, diabetes-related indications will likely receive better coverage than obesity indications. Eli Lilly will almost certainly offer a manufacturer savings card to reduce out-of-pocket costs, similar to the $25/month Zepbound card.\"}},{\"@type\":\"Question\",\"name\":\"What are the main side effects of retatrutide?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Side effect rates vary significantly by trial population. In TRIUMPH-4 (obesity + knee OA): nausea 43%, diarrhea 33%, dysesthesia 20.9%. In TRANSCEND-T2D-1 (type 2 diabetes): nausea 26.5%, diarrhea 22.8%, dysesthesia 4.4%. Heart rate increased by 4 to 7 beats per minute. Most side effects were mild to moderate and improved over time. See our retatrutide side effects guide for the full breakdown.\"}},{\"@type\":\"Question\",\"name\":\"Can a compounding pharmacy make retatrutide?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. US law only allows compounding of FDA-approved drugs. Since retatrutide has never been approved, compounding it is illegal. Even after eventual approval, compounding would only be permitted during a drug shortage. Eli Lilly is investing billions in manufacturing to prevent shortages like those that affected semaglutide and tirzepatide.\"}}]}"])

self.__next_f.push([1,"16:[\"$\",\"div\",null,{\"className\":\"min-h-screen bg-white\",\"children\":[[\"$\",\"$L1e\",null,{}],[\"$\",\"script\",null,{\"type\":\"application/ld+json\",\"dangerouslySetInnerHTML\":{\"__html\":\"{\\\"@context\\\":\\\"https://schema.org\\\",\\\"@type\\\":\\\"Article\\\",\\\"headline\\\":\\\"Retatrutide Availability \u0026 Timeline\\\",\\\"description\\\":\\\"Retatrutide is expected to receive FDA approval in mid-2027 with pharmacy availability in late 2027. Full timeline and Phase 3 trial status.\\\",\\\"image\\\":\\\"https://peptidesexplorer.com/images/blog/when-will-retatrutide-be-available-banner.webp\\\",\\\"datePublished\\\":\\\"2026-03-16\\\",\\\"dateModified\\\":\\\"2026-03-16\\\",\\\"author\\\":{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Doctor H\\\",\\\"url\\\":\\\"https://peptidesexplorer.com\\\"},\\\"publisher\\\":{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"PeptidesExplorer\\\",\\\"url\\\":\\\"https://peptidesexplorer.com\\\",\\\"logo\\\":{\\\"@type\\\":\\\"ImageObject\\\",\\\"url\\\":\\\"https://peptidesexplorer.com/favicon.ico\\\"}},\\\"mainEntityOfPage\\\":{\\\"@type\\\":\\\"WebPage\\\",\\\"@id\\\":\\\"https://peptidesexplorer.com/blog/when-will-retatrutide-be-available\\\"}}\"}}],[\"$\",\"script\",null,{\"type\":\"application/ld+json\",\"dangerouslySetInnerHTML\":{\"__html\":\"$1f\"}}],\"$L20\",\"$L21\",\"$L22\",\"$L23\"]}]\n"])

self.__next_f.push([1,"20:[\"$\",\"script\",null,{\"type\":\"application/ld+json\",\"dangerouslySetInnerHTML\":{\"__html\":\"{\\\"@context\\\":\\\"https://schema.org\\\",\\\"@type\\\":\\\"BreadcrumbList\\\",\\\"itemListElement\\\":[{\\\"@type\\\":\\\"ListItem\\\",\\\"position\\\":1,\\\"name\\\":\\\"Home\\\",\\\"item\\\":\\\"https://peptidesexplorer.com\\\"},{\\\"@type\\\":\\\"ListItem\\\",\\\"position\\\":2,\\\"name\\\":\\\"Blog\\\",\\\"item\\\":\\\"https://peptidesexplorer.com/blog\\\"},{\\\"@type\\\":\\\"ListItem\\\",\\\"position\\\":3,\\\"name\\\":\\\"Retatrutide Availability \u0026 Timeline\\\",\\\"item\\\":\\\"https://peptidesexplorer.com/blog/when-will-retatrutide-be-available\\\"}]}\"}}]\n"])

self.__next_f.push([1,"21:[\"$\",\"div\",null,{\"className\":\"bg-[#F8F8F8] border-b border-gray-200 py-12 px-4\",\"children\":[\"$\",\"div\",null,{\"className\":\"max-w-5xl mx-auto\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center gap-2 text-[#999] text-sm mb-4\",\"children\":[[\"$\",\"$L10\",null,{\"href\":\"/blog\",\"className\":\"hover:text-[#1526C9] transition-colors\",\"children\":\"Blog\"}],[\"$\",\"span\",null,{\"children\":\"/\"}],[\"$\",\"span\",null,{\"className\":\"text-[#111] line-clamp-1\",\"children\":\"Retatrutide Availability \u0026 Timeline\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-center gap-3 mb-4\",\"children\":[[\"$\",\"span\",null,{\"className\":\"text-xs font-semibold px-3 py-1 rounded-full border bg-cyan-50 text-cyan-600 border-cyan-200\",\"children\":\"Access Guides\"}],[\"$\",\"span\",null,{\"className\":\"text-[#999] text-sm\",\"children\":\"22 min read\"}]]}],[\"$\",\"h1\",null,{\"className\":\"text-3xl md:text-4xl font-bold text-[#111] mb-4 leading-tight\",\"children\":\"Retatrutide Availability \u0026 Timeline\"}],[\"$\",\"div\",null,{\"className\":\"flex items-center gap-4 text-[#999] text-sm\",\"children\":[[\"$\",\"time\",null,{\"dateTime\":\"2026-03-16\",\"children\":\"March 16, 2026\"}],[\"$\",\"span\",null,{\"children\":[\"By \",\"Doctor H\"]}]]}],[\"$\",\"div\",null,{\"className\":\"flex gap-2 mt-4 flex-wrap\",\"children\":[[\"$\",\"span\",\"Retatrutide\",{\"className\":\"text-xs bg-white text-[#666] px-3 py-1 rounded-full border border-gray-200\",\"children\":[\"#\",\"retatrutide\"]}],[\"$\",\"span\",\"FDA Approval\",{\"className\":\"text-xs bg-white text-[#666] px-3 py-1 rounded-full border border-gray-200\",\"children\":[\"#\",\"fdaapproval\"]}],[\"$\",\"span\",\"Eli Lilly\",{\"className\":\"text-xs bg-white text-[#666] px-3 py-1 rounded-full border border-gray-200\",\"children\":[\"#\",\"elililly\"]}],[\"$\",\"span\",\"Clinical Trials\",{\"className\":\"text-xs bg-white text-[#666] px-3 py-1 rounded-full border border-gray-200\",\"children\":[\"#\",\"clinicaltrials\"]}],[\"$\",\"span\",\"Weight Loss\",{\"className\":\"text-xs bg-white text-[#666] px-3 py-1 rounded-full border border-gray-200\",\"children\":[\"#\",\"weightloss\"]}],[\"$\",\"span\",\"GLP-1\",{\"className\":\"text-xs bg-white text-[#666] px-3 py-1 rounded-full border border-gray-200\",\"children\":[\"#\",\"glp-1\"]}],[\"$\",\"span\",\"Triple Agonist\",{\"className\":\"text-xs bg-white text-[#666] px-3 py-1 rounded-full border border-gray-200\",\"children\":[\"#\",\"tripleagonist\"]}],[\"$\",\"span\",\"TRIUMPH\",{\"className\":\"text-xs bg-white text-[#666] px-3 py-1 rounded-full border border-gray-200\",\"children\":[\"#\",\"triumph\"]}],[\"$\",\"span\",\"Tirzepatide\",{\"className\":\"text-xs bg-white text-[#666] px-3 py-1 rounded-full border border-gray-200\",\"children\":[\"#\",\"tirzepatide\"]}],[\"$\",\"span\",\"Semaglutide\",{\"className\":\"text-xs bg-white text-[#666] px-3 py-1 rounded-full border border-gray-200\",\"children\":[\"#\",\"semaglutide\"]}],[\"$\",\"span\",\"Obesity\",{\"className\":\"text-xs bg-white text-[#666] px-3 py-1 rounded-full border border-gray-200\",\"children\":[\"#\",\"obesity\"]}],[\"$\",\"span\",\"LY3437943\",{\"className\":\"text-xs bg-white text-[#666] px-3 py-1 rounded-full border border-gray-200\",\"children\":[\"#\",\"ly3437943\"]}]]}]]}]}]\n"])

self.__next_f.push([1,"22:[\"$\",\"div\",null,{\"className\":\"max-w-5xl mx-auto px-4 py-12\",\"children\":[\"$\",\"div\",null,{\"className\":\"flex flex-col lg:flex-row gap-10\",\"children\":[[\"$\",\"div\",null,{\"className\":\"hidden lg:block w-72 flex-shrink-0\",\"data-print-hide\":true,\"children\":[\"$\",\"div\",null,{\"className\":\"sticky top-24\",\"children\":[\"$\",\"div\",null,{\"className\":\"bg-white border border-gray-200 rounded-2xl p-6 shadow-sm\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"text-[#111] font-bold text-lg mb-4 leading-snug\",\"children\":\"Get your custom peptide protocol:\"}],[\"$\",\"ul\",null,{\"className\":\"space-y-3 mb-6\",\"children\":[[\"$\",\"li\",\"Tailored to your body and goals\",{\"className\":\"flex items-start gap-2.5 text-base text-[#666]\",\"children\":[[\"$\",\"svg\",null,{\"className\":\"w-5 h-5 text-[#1526C9] flex-shrink-0 mt-0.5\",\"fill\":\"none\",\"viewBox\":\"0 0 24 24\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"children\":[\"$\",\"path\",null,{\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"d\":\"M9 12.75L11.25 15 15 9.75M21 12a9 9 0 11-18 0 9 9 0 0118 0z\"}]}],[\"$\",\"span\",null,{\"children\":\"Tailored to your body and goals\"}]]}],[\"$\",\"li\",\"Precise dosing and cycle length\",{\"className\":\"flex items-start gap-2.5 text-base text-[#666]\",\"children\":[[\"$\",\"svg\",null,{\"className\":\"w-5 h-5 text-[#1526C9] flex-shrink-0 mt-0.5\",\"fill\":\"none\",\"viewBox\":\"0 0 24 24\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"children\":[\"$\",\"path\",null,{\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"d\":\"M9 12.75L11.25 15 15 9.75M21 12a9 9 0 11-18 0 9 9 0 0118 0z\"}]}],[\"$\",\"span\",null,{\"children\":\"Precise dosing and cycle length\"}]]}],[\"$\",\"li\",\"Safe stacking combinations\",{\"className\":\"flex items-start gap-2.5 text-base text-[#666]\",\"children\":[[\"$\",\"svg\",null,{\"className\":\"w-5 h-5 text-[#1526C9] flex-shrink-0 mt-0.5\",\"fill\":\"none\",\"viewBox\":\"0 0 24 24\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"children\":[\"$\",\"path\",null,{\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"d\":\"M9 12.75L11.25 15 15 9.75M21 12a9 9 0 11-18 0 9 9 0 0118 0z\"}]}],[\"$\",\"span\",null,{\"children\":\"Safe stacking combinations\"}]]}],[\"$\",\"li\",\"Backed by peer-reviewed studies\",{\"className\":\"flex items-start gap-2.5 text-base text-[#666]\",\"children\":[[\"$\",\"svg\",null,{\"className\":\"w-5 h-5 text-[#1526C9] flex-shrink-0 mt-0.5\",\"fill\":\"none\",\"viewBox\":\"0 0 24 24\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"children\":[\"$\",\"path\",null,{\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"d\":\"M9 12.75L11.25 15 15 9.75M21 12a9 9 0 11-18 0 9 9 0 0118 0z\"}]}],[\"$\",\"span\",null,{\"children\":\"Backed by peer-reviewed studies\"}]]}],[\"$\",\"li\",\"Ready in under 2 minutes\",{\"className\":\"flex items-start gap-2.5 text-base text-[#666]\",\"children\":[[\"$\",\"svg\",null,{\"className\":\"w-5 h-5 text-[#1526C9] flex-shrink-0 mt-0.5\",\"fill\":\"none\",\"viewBox\":\"0 0 24 24\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"children\":[\"$\",\"path\",null,{\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"d\":\"M9 12.75L11.25 15 15 9.75M21 12a9 9 0 11-18 0 9 9 0 0118 0z\"}]}],[\"$\",\"span\",null,{\"children\":\"Ready in under 2 minutes\"}]]}]]}],[\"$\",\"$L10\",null,{\"href\":\"/quiz\",\"className\":\"btn-pill block w-full text-center bg-[#1526C9] hover:bg-[#0f1d9a] text-white font-semibold py-3.5 rounded-full transition-colors\",\"children\":\"Start the Quiz →\"}]]}]}]}],[\"$\",\"article\",null,{\"className\":\"flex-1 min-w-0\",\"children\":[[\"$\",\"div\",null,{\"className\":\"mb-10\",\"children\":[\"$\",\"div\",null,{\"className\":\"space-y-4\",\"children\":[[\"$\",\"div\",\"0\",{\"className\":\"my-6\",\"children\":[\"$\",\"img\",null,{\"src\":\"/images/blog/when-will-retatrutide-be-available-banner.webp\",\"alt\":\"Retatrutide FDA approval timeline and availability guide\",\"className\":\"w-full h-auto rounded-xl border border-gray-200\",\"loading\":\"lazy\"}]}],[\"$\",\"p\",\"1\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"On December 19, 2025, Eli Lilly announced that \",[\"$\",\"$L10\",\"47\",{\"href\":\"/peptides/retatrutide\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"retatrutide\"}],\" produced 28.7% body weight loss in the Phase 3 TRIUMPH-4 trial. That translates to roughly 71 pounds off a 249-pound starting weight. \",[\"$\",\"strong\",\"218\",{\"className\":\"text-[#111] font-semibold\",\"children\":[\"Retatrutide is not available yet. The earliest realistic FDA approval date is mid-2027, with pharmacy shelves stocked by late 2027 or early 2028.\"]}]]}],\"$L24\",\"$L25\",\"$L26\",\"$L27\",\"$L28\"]}]}],false,\"$L29\",[\"$L2a\",\"$L2b\",\"$L2c\",\"$L2d\",\"$L2e\",\"$L2f\",\"$L30\",\"$L31\",\"$L32\",\"$L33\",\"$L34\"],\"$L35\",\"$L36\",\"$L37\",\"$L38\",\"$L39\"]}]]}]}]\n"])

self.__next_f.push([1,"23:[\"$\",\"div\",null,{\"className\":\"bg-[#F8F8F8] border-t border-gray-200\",\"data-print-hide\":true,\"children\":[\"$\",\"div\",null,{\"className\":\"max-w-3xl mx-auto px-4 py-20 text-center\",\"children\":[[\"$\",\"h2\",null,{\"className\":\"text-3xl md:text-4xl font-bold text-[#111] mb-4 leading-tight\",\"children\":\"Ready to optimize your peptide protocol?\"}],[\"$\",\"p\",null,{\"className\":\"text-[#666] text-lg mb-8 max-w-xl mx-auto\",\"children\":\"Get a personalized plan based on your goals, body, and experience level. Takes under 2 minutes.\"}],[\"$\",\"$L10\",null,{\"href\":\"/quiz\",\"className\":\"btn-pill inline-flex items-center bg-[#1526C9] hover:bg-[#0f1d9a] text-white font-bold text-lg px-10 py-4 rounded-full transition-colors\",\"children\":\"Start the Quiz →\"}]]}]}]\n"])

self.__next_f.push([1,"24:[\"$\",\"p\",\"2\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Think of the drug approval process like building a house. You need architectural plans (Phase 3 data), a building permit (FDA submission), an inspection (FDA review), and finally a certificate of occupancy (approval) before anyone can move in. Retatrutide is still in the architectural plans phase. Seven large-scale trials are running. Two will finish mid-2026. Then Eli Lilly files the paperwork, the FDA reviews it for 6 to 10 months, and only then can your doctor write a prescription.\"]}]\n"])

self.__next_f.push([1,"25:[\"$\",\"div\",\"3\",{\"children\":[\"$\",\"div\",null,{\"className\":\"overflow-x-auto rounded-xl border border-gray-200\",\"children\":[\"$\",\"table\",null,{\"className\":\"w-full text-sm\",\"children\":[[\"$\",\"thead\",null,{\"children\":[\"$\",\"tr\",null,{\"className\":\"bg-[#F8F8F8]\",\"children\":[[\"$\",\"th\",\"0\",{\"className\":\"text-left text-[#111] font-semibold px-4 py-3 border-b border-gray-200\",\"children\":[\"Quick Reference\"]}],[\"$\",\"th\",\"1\",{\"className\":\"text-left text-[#111] font-semibold px-4 py-3 border-b border-gray-200\",\"children\":[\"Details\"]}]]}]}],[\"$\",\"tbody\",null,{\"children\":[[\"$\",\"tr\",\"0\",{\"className\":\"\",\"children\":[[\"$\",\"td\",\"0\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Drug name\"]}],[\"$\",\"td\",\"1\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Retatrutide (LY3437943)\"]}]]}],[\"$\",\"tr\",\"1\",{\"className\":\"bg-[#FAFAFA]\",\"children\":[[\"$\",\"td\",\"0\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Manufacturer\"]}],[\"$\",\"td\",\"1\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Eli Lilly and Company\"]}]]}],[\"$\",\"tr\",\"2\",{\"className\":\"\",\"children\":[[\"$\",\"td\",\"0\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Mechanism\"]}],[\"$\",\"td\",\"1\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Triple agonist: GLP-1 + GIP + Glucagon\"]}]]}],[\"$\",\"tr\",\"3\",{\"className\":\"bg-[#FAFAFA]\",\"children\":[[\"$\",\"td\",\"0\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Max weight loss in trials\"]}],[\"$\",\"td\",\"1\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"28.7% body weight (71 lbs) at 68 weeks\"]}]]}],[\"$\",\"tr\",\"4\",{\"className\":\"\",\"children\":[[\"$\",\"td\",\"0\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Current status\"]}],[\"$\",\"td\",\"1\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Phase 3 clinical trials (not approved anywhere)\"]}]]}],[\"$\",\"tr\",\"5\",{\"className\":\"bg-[#FAFAFA]\",\"children\":[[\"$\",\"td\",\"0\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Expected NDA submission\"]}],[\"$\",\"td\",\"1\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Late 2026\"]}]]}],[\"$\",\"tr\",\"6\",{\"className\":\"\",\"children\":[[\"$\",\"td\",\"0\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Expected FDA decision\"]}],[\"$\",\"td\",\"1\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Mid-2027\"]}]]}],[\"$\",\"tr\",\"7\",{\"className\":\"bg-[#FAFAFA]\",\"children\":[[\"$\",\"td\",\"0\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Expected pharmacy availability\"]}],[\"$\",\"td\",\"1\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Late 2027 to early 2028\"]}]]}],[\"$\",\"tr\",\"8\",{\"className\":\"\",\"children\":[[\"$\",\"td\",\"0\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Current access options\"]}],[\"$\",\"td\",\"1\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Clinical trials, expanded access (rare)\"]}]]}]]}]]}]}]}]\n"])

self.__next_f.push([1,"26:[\"$\",\"div\",\"4\",{\"className\":\"my-6\",\"children\":[\"$\",\"img\",null,{\"src\":\"/images/blog/when-will-retatrutide-be-available-timeline.webp\",\"alt\":\"Retatrutide FDA approval timeline showing Phase 3 trials through commercial launch\",\"className\":\"w-full h-auto rounded-xl border border-gray-200\",\"loading\":\"lazy\"}]}]\n27:[\"$\",\"p\",\"5\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"This article walks through every milestone between now and the day you can fill a retatrutide prescription. We cover where each Phase 3 trial stands, what Eli Lilly has said publicly, how this timeline compares to \",[\"$\",\"$L10\",\"214\",{\"href\":\"/peptides/semaglutide\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"semaglutide\"}],\" and \",[\"$\",\"$L10\",\"255\",{\"href\":\"/peptides/tirzepatide\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"tirzepatide\"}],\" approvals, and what you can do while waiting. For a complete overview of the drug itself, see our \",[\"$\",\"$L10\",\"390\",{\"href\":\"/blog/retatrutide\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"retatrutide guide\"}],\". For side effect data, see \",[\"$\",\"$L10\",\"456\",{\"href\":\"/blog/retatrutide-side-effects\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"retatrutide side effects\"}],\".\"]}]\n28:[\"$\",\"p\",\"6\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"This is educational content about an experimental drug. Consult a healthcare provider before making any medical decisions.\"]}]\n"])

self.__next_f.push([1,"29:[\"$\",\"div\",null,{\"className\":\"lg:hidden mb-10\",\"data-print-hide\":true,\"children\":[\"$\",\"div\",null,{\"className\":\"sticky top-24\",\"children\":[\"$\",\"div\",null,{\"className\":\"bg-white border border-gray-200 rounded-2xl p-6 shadow-sm\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"text-[#111] font-bold text-lg mb-4 leading-snug\",\"children\":\"Get your custom peptide protocol:\"}],[\"$\",\"ul\",null,{\"className\":\"space-y-3 mb-6\",\"children\":[[\"$\",\"li\",\"Tailored to your body and goals\",{\"className\":\"flex items-start gap-2.5 text-base text-[#666]\",\"children\":[[\"$\",\"svg\",null,{\"className\":\"w-5 h-5 text-[#1526C9] flex-shrink-0 mt-0.5\",\"fill\":\"none\",\"viewBox\":\"0 0 24 24\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"children\":[\"$\",\"path\",null,{\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"d\":\"M9 12.75L11.25 15 15 9.75M21 12a9 9 0 11-18 0 9 9 0 0118 0z\"}]}],[\"$\",\"span\",null,{\"children\":\"Tailored to your body and goals\"}]]}],[\"$\",\"li\",\"Precise dosing and cycle length\",{\"className\":\"flex items-start gap-2.5 text-base text-[#666]\",\"children\":[[\"$\",\"svg\",null,{\"className\":\"w-5 h-5 text-[#1526C9] flex-shrink-0 mt-0.5\",\"fill\":\"none\",\"viewBox\":\"0 0 24 24\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"children\":[\"$\",\"path\",null,{\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"d\":\"M9 12.75L11.25 15 15 9.75M21 12a9 9 0 11-18 0 9 9 0 0118 0z\"}]}],[\"$\",\"span\",null,{\"children\":\"Precise dosing and cycle length\"}]]}],[\"$\",\"li\",\"Safe stacking combinations\",{\"className\":\"flex items-start gap-2.5 text-base text-[#666]\",\"children\":[[\"$\",\"svg\",null,{\"className\":\"w-5 h-5 text-[#1526C9] flex-shrink-0 mt-0.5\",\"fill\":\"none\",\"viewBox\":\"0 0 24 24\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"children\":[\"$\",\"path\",null,{\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"d\":\"M9 12.75L11.25 15 15 9.75M21 12a9 9 0 11-18 0 9 9 0 0118 0z\"}]}],[\"$\",\"span\",null,{\"children\":\"Safe stacking combinations\"}]]}],[\"$\",\"li\",\"Backed by peer-reviewed studies\",{\"className\":\"flex items-start gap-2.5 text-base text-[#666]\",\"children\":[[\"$\",\"svg\",null,{\"className\":\"w-5 h-5 text-[#1526C9] flex-shrink-0 mt-0.5\",\"fill\":\"none\",\"viewBox\":\"0 0 24 24\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"children\":[\"$\",\"path\",null,{\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"d\":\"M9 12.75L11.25 15 15 9.75M21 12a9 9 0 11-18 0 9 9 0 0118 0z\"}]}],[\"$\",\"span\",null,{\"children\":\"Backed by peer-reviewed studies\"}]]}],[\"$\",\"li\",\"Ready in under 2 minutes\",{\"className\":\"flex items-start gap-2.5 text-base text-[#666]\",\"children\":[[\"$\",\"svg\",null,{\"className\":\"w-5 h-5 text-[#1526C9] flex-shrink-0 mt-0.5\",\"fill\":\"none\",\"viewBox\":\"0 0 24 24\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"children\":[\"$\",\"path\",null,{\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"d\":\"M9 12.75L11.25 15 15 9.75M21 12a9 9 0 11-18 0 9 9 0 0118 0z\"}]}],[\"$\",\"span\",null,{\"children\":\"Ready in under 2 minutes\"}]]}]]}],[\"$\",\"$L10\",null,{\"href\":\"/quiz\",\"className\":\"btn-pill block w-full text-center bg-[#1526C9] hover:bg-[#0f1d9a] text-white font-semibold py-3.5 rounded-full transition-colors\",\"children\":\"Start the Quiz →\"}]]}]}]}]\n"])

self.__next_f.push([1,"2a:[\"$\",\"div\",\"0\",{\"children\":[[\"$\",\"div\",null,{\"className\":\"mb-10\",\"children\":[[\"$\",\"h2\",null,{\"id\":\"where-does-retatrutide-stand-right-now\",\"className\":\"text-2xl font-bold text-[#111] mb-4\",\"children\":\"Where Does Retatrutide Stand Right Now?\"}],[\"$\",\"div\",null,{\"className\":\"mb-6\",\"children\":[\"$\",\"div\",null,{\"className\":\"space-y-4\",\"children\":[[\"$\",\"p\",\"0\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"As of March 2026, retatrutide is an investigational drug in Phase 3 clinical trials. No regulatory agency on Earth has approved it. You cannot get a prescription for it from any doctor, and no pharmacy can legally dispense it.\"]}],[\"$\",\"p\",\"1\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Here is what that means in practical terms. Phase 3 is the final and largest testing phase before a company can ask the FDA for approval. Eli Lilly is running eight trials under the umbrella name TRIUMPH, enrolling over 5,800 patients across multiple countries. These trials test retatrutide for obesity, type 2 diabetes, cardiovascular disease, knee osteoarthritis, and liver disease (\",[\"$\",\"a\",\"386\",{\"href\":\"https://pubmed.ncbi.nlm.nih.gov/41090431/\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"Giblin et al., Diabetes, Obesity and Metabolism 2026\"}],\").\"]}],[\"$\",\"p\",\"2\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"One trial has already finished. TRIUMPH-4 (445 patients with knee osteoarthritis) reported results in December 2025, showing the 28.7% weight loss figure that made headlines worldwide (\",[\"$\",\"a\",\"185\",{\"href\":\"https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"Lilly Press Release, Dec 2025\"}],\"). The remaining trials are still active and will report throughout 2026.\"]}]]}]}],[\"$\",\"div\",null,{\"className\":\"space-y-4 mt-4\",\"children\":[[\"$\",\"div\",\"0\",{\"className\":\"bg-[#F8F8F8] border-l-4 border-[#1526C9] p-5 rounded-r-xl\",\"children\":[[\"$\",\"h3\",null,{\"id\":\"the-triumph-trial-program-trial-by-trial-status\",\"className\":\"text-lg font-bold text-[#111] mb-2\",\"children\":\"The TRIUMPH Trial Program: Trial-by-Trial Status\"}],[\"$\",\"div\",null,{\"className\":\"text-sm\",\"children\":[\"$\",\"div\",null,{\"className\":\"space-y-4\",\"children\":[[\"$\",\"p\",\"0\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Each trial in the TRIUMPH program serves a specific purpose. The FDA needs data across different patient populations to feel confident that the drug is both safe and effective broadly, not just in one narrow group.\"]}],[\"$\",\"div\",\"1\",{\"children\":[\"$\",\"div\",null,{\"className\":\"overflow-x-auto rounded-xl border border-gray-200\",\"children\":[\"$\",\"table\",null,{\"className\":\"w-full text-sm\",\"children\":[[\"$\",\"thead\",null,{\"children\":[\"$\",\"tr\",null,{\"className\":\"bg-[#F8F8F8]\",\"children\":[[\"$\",\"th\",\"0\",{\"className\":\"text-left text-[#111] font-semibold px-4 py-3 border-b border-gray-200\",\"children\":[\"Trial\"]}],[\"$\",\"th\",\"1\",{\"className\":\"text-left text-[#111] font-semibold px-4 py-3 border-b border-gray-200\",\"children\":[\"Focus\"]}],[\"$\",\"th\",\"2\",{\"className\":\"text-left text-[#111] font-semibold px-4 py-3 border-b border-gray-200\",\"children\":[\"Patients\"]}],[\"$\",\"th\",\"3\",{\"className\":\"text-left text-[#111] font-semibold px-4 py-3 border-b border-gray-200\",\"children\":[\"NCT ID\"]}],[\"$\",\"th\",\"4\",{\"className\":\"text-left text-[#111] font-semibold px-4 py-3 border-b border-gray-200\",\"children\":[\"Status (March 2026)\"]}]]}]}],[\"$\",\"tbody\",null,{\"children\":[[\"$\",\"tr\",\"0\",{\"className\":\"\",\"children\":[[\"$\",\"td\",\"0\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"TRIUMPH-1\"]}],[\"$\",\"td\",\"1\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Obesity (primary)\"]}],\"$L3a\",\"$L3b\",\"$L3c\"]}],\"$L3d\",\"$L3e\",\"$L3f\",\"$L40\",\"$L41\",\"$L42\",\"$L43\"]}]]}]}]}],\"$L44\",\"$L45\"]}]}]]}],\"$L46\"]}]]}],false]}]\n"])

self.__next_f.push([1,"2b:[\"$\",\"div\",\"1\",{\"children\":[[\"$\",\"div\",null,{\"className\":\"mb-10\",\"children\":[[\"$\",\"h2\",null,{\"id\":\"the-fda-approval-timeline-step-by-step\",\"className\":\"text-2xl font-bold text-[#111] mb-4\",\"children\":\"The FDA Approval Timeline: Step by Step\"}],[\"$\",\"div\",null,{\"className\":\"mb-6\",\"children\":[\"$\",\"div\",null,{\"className\":\"space-y-4\",\"children\":[[\"$\",\"p\",\"0\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Drug approval is not a single event. It is a sequence of regulatory steps, each with its own timeline. No step can be skipped, and each one must be completed before the next can begin.\"]}]]}]}],[\"$\",\"div\",null,{\"className\":\"space-y-4 mt-4\",\"children\":[[\"$\",\"div\",\"0\",{\"className\":\"bg-[#F8F8F8] border-l-4 border-[#1526C9] p-5 rounded-r-xl\",\"children\":[[\"$\",\"h3\",null,{\"id\":\"step-1-complete-pivotal-trials-mid-2026\",\"className\":\"text-lg font-bold text-[#111] mb-2\",\"children\":\"Step 1: Complete Pivotal Trials (Mid-2026)\"}],[\"$\",\"div\",null,{\"className\":\"text-sm\",\"children\":[\"$\",\"div\",null,{\"className\":\"space-y-4\",\"children\":[[\"$\",\"p\",\"0\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Eli Lilly needs final data from TRIUMPH-1 (2,300 obesity patients) and TRIUMPH-2 (1,000 type 2 diabetes patients). These are the trials the FDA will scrutinize most closely. Both are expected to deliver top-line results around the middle of 2026.\"]}],[\"$\",\"p\",\"1\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"\\\"Top-line results\\\" means the key findings: did people lose significantly more weight than placebo, and was the drug safe enough? The detailed analysis, including subgroup breakdowns, long-term safety data, and secondary endpoints, takes additional months to compile.\"]}],[\"$\",\"p\",\"2\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Based on TRIUMPH-4 and Phase 2 data, analysts widely expect positive results. But biology can surprise. If a serious safety signal emerges in a larger population, the timeline could extend by a year or more. In the Phase 3 TRIUMPH-4 trial, a new safety signal called dysesthesia (abnormal skin sensations like tingling or burning) appeared in up to 20.9% of patients on the highest dose. The FDA will want to understand this signal fully before approving the drug. For details on known side effects, see our \",[\"$\",\"$L10\",\"508\",{\"href\":\"/blog/retatrutide-side-effects\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"retatrutide side effects guide\"}],\".\"]}]]}]}]]}],[\"$\",\"div\",\"1\",{\"className\":\"bg-[#F8F8F8] border-l-4 border-[#1526C9] p-5 rounded-r-xl\",\"children\":[[\"$\",\"h3\",null,{\"id\":\"step-2-assemble-and-submit-the-nda-late-2026\",\"className\":\"text-lg font-bold text-[#111] mb-2\",\"children\":\"Step 2: Assemble and Submit the NDA (Late 2026)\"}],[\"$\",\"div\",null,{\"className\":\"text-sm\",\"children\":[\"$\",\"div\",null,{\"className\":\"space-y-4\",\"children\":[[\"$\",\"p\",\"0\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"After the pivotal trials finish, Eli Lilly assembles a New Drug Application (NDA). This is a massive document, sometimes exceeding 100,000 pages, that contains every piece of data the FDA needs to evaluate the drug: efficacy results, safety data, manufacturing details, proposed labeling, and the plan for post-approval monitoring.\"]}],[\"$\",\"p\",\"1\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Preparing an NDA typically takes 4 to 6 months after the last pivotal trial reports. Analysts expect Lilly to submit in late 2026, possibly Q4. The company has not publicly confirmed a submission date, but its quarterly investor calls have consistently described retatrutide as a \\\"late-stage pipeline priority.\\\"\"]}],[\"$\",\"p\",\"2\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Lilly could also pursue a pre-NDA meeting with the FDA, where the agency provides informal guidance on what the application should contain. This meeting helps avoid last-minute surprises that could delay the review. Given the scale and importance of the TRIUMPH program, a pre-NDA meeting is almost certain.\"]}]]}]}]]}],\"$L47\",\"$L48\",\"$L49\"]}]]}],false]}]\n"])

self.__next_f.push([1,"2c:[\"$\",\"div\",\"2\",{\"children\":[[\"$\",\"div\",null,{\"className\":\"mb-10\",\"children\":[[\"$\",\"h2\",null,{\"id\":\"how-retatrutide-s-timeline-compares-to-semaglutide-and-tirzepatide\",\"className\":\"text-2xl font-bold text-[#111] mb-4\",\"children\":\"How Retatrutide's Timeline Compares to Semaglutide and Tirzepatide\"}],[\"$\",\"div\",null,{\"className\":\"mb-6\",\"children\":[\"$\",\"div\",null,{\"className\":\"space-y-4\",\"children\":[[\"$\",\"div\",\"0\",{\"className\":\"my-6\",\"children\":[\"$\",\"img\",null,{\"src\":\"/images/blog/when-will-retatrutide-be-available-comparison.webp\",\"alt\":\"Comparison of FDA approval timelines for semaglutide, tirzepatide, and retatrutide\",\"className\":\"w-full h-auto rounded-xl border border-gray-200\",\"loading\":\"lazy\"}]}],[\"$\",\"p\",\"1\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Historical comparisons help calibrate expectations. Both \",[\"$\",\"$L10\",\"57\",{\"href\":\"/peptides/semaglutide\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"semaglutide\"}],\" and \",[\"$\",\"$L10\",\"98\",{\"href\":\"/peptides/tirzepatide\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"tirzepatide\"}],\" followed similar paths to the one retatrutide is on now. Looking at their timelines reveals how long each step actually took.\"]}]]}]}],[\"$\",\"div\",null,{\"className\":\"space-y-4 mt-4\",\"children\":[[\"$\",\"div\",\"0\",{\"className\":\"bg-[#F8F8F8] border-l-4 border-[#1526C9] p-5 rounded-r-xl\",\"children\":[[\"$\",\"h3\",null,{\"id\":\"semaglutide-from-phase-3-to-pharmacy-in-3-years\",\"className\":\"text-lg font-bold text-[#111] mb-2\",\"children\":\"Semaglutide: From Phase 3 to Pharmacy in 3 Years\"}],[\"$\",\"div\",null,{\"className\":\"text-sm\",\"children\":[\"$\",\"div\",null,{\"className\":\"space-y-4\",\"children\":[[\"$\",\"p\",\"0\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Novo Nordisk began the STEP clinical trial program for semaglutide (Wegovy) in 2018. The STEP 1 trial published results in the New England Journal of Medicine in February 2021, showing 14.9% weight loss at 68 weeks (\",[\"$\",\"a\",\"216\",{\"href\":\"https://pubmed.ncbi.nlm.nih.gov/33567185\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"Wilding et al., NEJM 2021\"}],\").\"]}],[\"$\",\"p\",\"1\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"The NDA for Wegovy was submitted in December 2020, before the pivotal trial was even published. The FDA approved Wegovy on June 4, 2021, using Priority Review. Total time from first Phase 3 enrollment to approval: roughly 3 years. However, supply shortages delayed widespread availability until late 2023.\"]}],[\"$\",\"div\",\"2\",{\"children\":[\"$\",\"div\",null,{\"className\":\"overflow-x-auto rounded-xl border border-gray-200\",\"children\":[\"$\",\"table\",null,{\"className\":\"w-full text-sm\",\"children\":[[\"$\",\"thead\",null,{\"children\":[\"$\",\"tr\",null,{\"className\":\"bg-[#F8F8F8]\",\"children\":[[\"$\",\"th\",\"0\",{\"className\":\"text-left text-[#111] font-semibold px-4 py-3 border-b border-gray-200\",\"children\":[\"Semaglutide (Wegovy)\"]}],[\"$\",\"th\",\"1\",{\"className\":\"text-left text-[#111] font-semibold px-4 py-3 border-b border-gray-200\",\"children\":[\"Date\"]}]]}]}],[\"$\",\"tbody\",null,{\"children\":[[\"$\",\"tr\",\"0\",{\"className\":\"\",\"children\":[[\"$\",\"td\",\"0\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"STEP 1 trial start\"]}],[\"$\",\"td\",\"1\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"June 2018\"]}]]}],[\"$\",\"tr\",\"1\",{\"className\":\"bg-[#FAFAFA]\",\"children\":[[\"$\",\"td\",\"0\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"NDA submission\"]}],[\"$\",\"td\",\"1\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"December 2020\"]}]]}],[\"$\",\"tr\",\"2\",{\"className\":\"\",\"children\":[[\"$\",\"td\",\"0\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"FDA approval\"]}],[\"$\",\"td\",\"1\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"June 2021\"]}]]}],[\"$\",\"tr\",\"3\",{\"className\":\"bg-[#FAFAFA]\",\"children\":[[\"$\",\"td\",\"0\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Widespread availability\"]}],\"$L4a\"]}]]}]]}]}]}],\"$L4b\"]}]}]]}],\"$L4c\",\"$L4d\"]}]]}],false]}]\n"])

self.__next_f.push([1,"2d:[\"$\",\"div\",\"3\",{\"children\":[[\"$\",\"div\",null,{\"className\":\"mb-10\",\"children\":[[\"$\",\"h2\",null,{\"id\":\"why-is-the-approval-taking-so-long\",\"className\":\"text-2xl font-bold text-[#111] mb-4\",\"children\":\"Why Is the Approval Taking So Long?\"}],[\"$\",\"div\",null,{\"className\":\"mb-6\",\"children\":[\"$\",\"div\",null,{\"className\":\"space-y-4\",\"children\":[[\"$\",\"p\",\"0\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"If retatrutide works so well, why not fast-track it immediately? The answer comes down to safety, scale, and regulatory precedent.\"]}]]}]}],[\"$\",\"div\",null,{\"className\":\"space-y-4 mt-4\",\"children\":[[\"$\",\"div\",\"0\",{\"className\":\"bg-[#F8F8F8] border-l-4 border-[#1526C9] p-5 rounded-r-xl\",\"children\":[[\"$\",\"h3\",null,{\"id\":\"the-fda-requires-large-scale-safety-data\",\"className\":\"text-lg font-bold text-[#111] mb-2\",\"children\":\"The FDA Requires Large-Scale Safety Data\"}],[\"$\",\"div\",null,{\"className\":\"text-sm\",\"children\":[\"$\",\"div\",null,{\"className\":\"space-y-4\",\"children\":[[\"$\",\"p\",\"0\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Phase 2 tested retatrutide in 338 people. That is enough to confirm the drug works but not enough to catch rare side effects that might affect 1 in 500 or 1 in 1,000 patients. The Phase 3 TRIUMPH program enrolls over 5,800 people specifically to find those rare events.\"]}],[\"$\",\"p\",\"1\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Consider the math. A side effect that occurs in 0.1% of patients (1 in 1,000) has only a 28% chance of appearing in a 338-person trial. In a 5,800-person program, that same side effect has a 99.7% chance of being detected. The FDA wants that 99.7% confidence level before 50 million Americans start taking a new weight loss drug (\",[\"$\",\"a\",\"330\",{\"href\":\"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e9-statistical-principles-clinical-trials\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"FDA Guidance on Clinical Trial Size\"}],\").\"]}],[\"$\",\"p\",\"2\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"The dysesthesia signal illustrates why this matters. It was barely noticeable in Phase 2 but appeared in up to 20.9% of patients on the highest dose in Phase 3. Without the larger trial, this side effect might not have been characterized until after millions of people were already taking the drug.\"]}]]}]}]]}],[\"$\",\"div\",\"1\",{\"className\":\"bg-[#F8F8F8] border-l-4 border-[#1526C9] p-5 rounded-r-xl\",\"children\":[[\"$\",\"h3\",null,{\"id\":\"the-glucagon-component-is-uncharted-territory\",\"className\":\"text-lg font-bold text-[#111] mb-2\",\"children\":\"The Glucagon Component Is Uncharted Territory\"}],[\"$\",\"div\",null,{\"className\":\"text-sm\",\"children\":[\"$\",\"div\",null,{\"className\":\"space-y-4\",\"children\":[[\"$\",\"p\",\"0\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Every currently approved weight loss drug works through GLP-1 alone (semaglutide) or GLP-1 plus GIP (tirzepatide). Retatrutide adds glucagon receptor activation, something no approved drug does. The FDA has no direct precedent for reviewing a glucagon agonist for chronic weight management.\"]}],[\"$\",\"p\",\"1\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Glucagon's primary natural role is raising blood sugar when it drops too low. A drug that activates glucagon receptors carries theoretical risks: it could raise fasting blood sugar, accelerate muscle protein breakdown, or overstimulate the heart. In the clinical trials so far, blood sugar effects have been manageable (retatrutide actually improved blood sugar in diabetic patients), and muscle loss has been proportional to weight loss. The heart rate increase of 4 to 7 beats per minute is within acceptable range but requires monitoring (\",\"$L4e\",\").\"]}],\"$L4f\"]}]}]]}],\"$L50\"]}]]}],false]}]\n"])

self.__next_f.push([1,"2e:[\"$\",\"div\",\"4\",{\"children\":[[\"$\",\"div\",null,{\"className\":\"mb-10\",\"children\":[[\"$\",\"h2\",null,{\"id\":\"can-you-access-retatrutide-before-fda-approval\",\"className\":\"text-2xl font-bold text-[#111] mb-4\",\"children\":\"Can You Access Retatrutide Before FDA Approval?\"}],[\"$\",\"div\",null,{\"className\":\"mb-6\",\"children\":[\"$\",\"div\",null,{\"className\":\"space-y-4\",\"children\":[[\"$\",\"p\",\"0\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Yes, but only through narrow channels. There is no legal way to get a retatrutide prescription today. There are, however, two legitimate pathways and one gray-market option. For a comprehensive walkthrough, see our \",[\"$\",\"$L10\",\"215\",{\"href\":\"/blog/retatrutide-how-to-get\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"retatrutide: how to get it\"}],\" guide.\"]}]]}]}],[\"$\",\"div\",null,{\"className\":\"space-y-4 mt-4\",\"children\":[[\"$\",\"div\",\"0\",{\"className\":\"bg-[#F8F8F8] border-l-4 border-[#1526C9] p-5 rounded-r-xl\",\"children\":[[\"$\",\"h3\",null,{\"id\":\"clinical-trials-the-primary-access-route\",\"className\":\"text-lg font-bold text-[#111] mb-2\",\"children\":\"Clinical Trials: The Primary Access Route\"}],[\"$\",\"div\",null,{\"className\":\"text-sm\",\"children\":[\"$\",\"div\",null,{\"className\":\"space-y-4\",\"children\":[[\"$\",\"p\",\"0\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Enrolling in a TRIUMPH trial is the only way to receive pharmaceutical-grade retatrutide under medical supervision. Everything is free: the drug, doctor visits, lab work, and monitoring. You may receive placebo (an inactive injection), but even placebo participants get extensive medical care throughout the study.\"]}],[\"$\",\"p\",\"1\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"To find active trials near you, go to \",[\"$\",\"a\",\"38\",{\"href\":\"https://clinicaltrials.gov\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"ClinicalTrials.gov\"}],\" and search for \\\"retatrutide,\\\" or visit Eli Lilly's trial finder at \",[\"$\",\"a\",\"154\",{\"href\":\"https://trials.lilly.com\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"trials.lilly.com\"}],\". General eligibility requirements include a BMI of 30 or higher (or 27+ with a weight-related health condition), age 18 or older, and no history of pancreatitis or medullary thyroid carcinoma.\"]}],[\"$\",\"p\",\"2\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"As of March 2026, two trials are actively recruiting new participants: the Maintenance trial (NCT06859268, testing dose reduction after initial weight loss) and a new enrollment trial (NCT07232719, 250 participants with obesity or overweight). Competition for spots is intense. Apply early and be prepared for a screening process that typically takes 2 to 4 weeks.\"]}]]}]}]]}],[\"$\",\"div\",\"1\",{\"className\":\"bg-[#F8F8F8] border-l-4 border-[#1526C9] p-5 rounded-r-xl\",\"children\":[[\"$\",\"h3\",null,{\"id\":\"expanded-access-compassionate-use\",\"className\":\"text-lg font-bold text-[#111] mb-2\",\"children\":\"Expanded Access (Compassionate Use)\"}],[\"$\",\"div\",null,{\"className\":\"text-sm\",\"children\":[\"$\",\"div\",null,{\"className\":\"space-y-4\",\"children\":[[\"$\",\"p\",\"0\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"If you have a life-threatening obesity-related condition, have exhausted all approved treatments, and cannot enroll in a clinical trial, your doctor can request expanded access directly from Eli Lilly. Call 1-800-545-5979. The company responds within 5 business days.\"]}],[\"$\",\"p\",\"1\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"This pathway is extremely narrow. Being overweight, even severely overweight, typically does not qualify. You would need complications like severe heart failure, respiratory failure, or organ damage directly attributable to obesity. Fewer than 1% of requests are granted for experimental weight loss drugs.\"]}]]}]}]]}],\"$L51\"]}]]}],false]}]\n"])

self.__next_f.push([1,"2f:[\"$\",\"div\",\"5\",{\"children\":[[\"$\",\"div\",null,{\"className\":\"mb-10\",\"children\":[[\"$\",\"h2\",null,{\"id\":\"what-will-retatrutide-cost-when-it-becomes-available\",\"className\":\"text-2xl font-bold text-[#111] mb-4\",\"children\":\"What Will Retatrutide Cost When It Becomes Available?\"}],[\"$\",\"div\",null,{\"className\":\"mb-6\",\"children\":[\"$\",\"div\",null,{\"className\":\"space-y-4\",\"children\":[[\"$\",\"p\",\"0\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Nobody knows the exact price yet, but Eli Lilly's pricing history with tirzepatide provides a reasonable estimate.\"]}]]}]}],[\"$\",\"div\",null,{\"className\":\"space-y-4 mt-4\",\"children\":[[\"$\",\"div\",\"0\",{\"className\":\"bg-[#F8F8F8] border-l-4 border-[#1526C9] p-5 rounded-r-xl\",\"children\":[[\"$\",\"h3\",null,{\"id\":\"expected-retail-pricing\",\"className\":\"text-lg font-bold text-[#111] mb-2\",\"children\":\"Expected Retail Pricing\"}],[\"$\",\"div\",null,{\"className\":\"text-sm\",\"children\":[\"$\",\"div\",null,{\"className\":\"space-y-4\",\"children\":[[\"$\",\"p\",\"0\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Zepbound (tirzepatide for weight loss) launched at $1,059.87 per month. Mounjaro (tirzepatide for diabetes) was priced at $1,023.04 per month. Retatrutide will almost certainly fall in a similar range, possibly slightly higher given the additional receptor target and superior efficacy data.\"]}],[\"$\",\"p\",\"1\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"For context, Wegovy (semaglutide for weight loss) costs $1,349.02 per month. Ozempic (semaglutide for diabetes) costs $935.77 per month. Weight loss drugs from the same manufacturer tend to be priced at a premium over diabetes versions of similar drugs.\"]}],[\"$\",\"div\",\"2\",{\"children\":[\"$\",\"div\",null,{\"className\":\"overflow-x-auto rounded-xl border border-gray-200\",\"children\":[\"$\",\"table\",null,{\"className\":\"w-full text-sm\",\"children\":[[\"$\",\"thead\",null,{\"children\":[\"$\",\"tr\",null,{\"className\":\"bg-[#F8F8F8]\",\"children\":[[\"$\",\"th\",\"0\",{\"className\":\"text-left text-[#111] font-semibold px-4 py-3 border-b border-gray-200\",\"children\":[\"Drug\"]}],[\"$\",\"th\",\"1\",{\"className\":\"text-left text-[#111] font-semibold px-4 py-3 border-b border-gray-200\",\"children\":[\"Monthly List Price\"]}],[\"$\",\"th\",\"2\",{\"className\":\"text-left text-[#111] font-semibold px-4 py-3 border-b border-gray-200\",\"children\":[\"Manufacturer\"]}]]}]}],[\"$\",\"tbody\",null,{\"children\":[[\"$\",\"tr\",\"0\",{\"className\":\"\",\"children\":[[\"$\",\"td\",\"0\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Wegovy (semaglutide)\"]}],[\"$\",\"td\",\"1\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"$$1,349\"]}],[\"$\",\"td\",\"2\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Novo Nordisk\"]}]]}],[\"$\",\"tr\",\"1\",{\"className\":\"bg-[#FAFAFA]\",\"children\":[[\"$\",\"td\",\"0\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Ozempic (semaglutide)\"]}],[\"$\",\"td\",\"1\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"$$936\"]}],[\"$\",\"td\",\"2\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Novo Nordisk\"]}]]}],[\"$\",\"tr\",\"2\",{\"className\":\"\",\"children\":[[\"$\",\"td\",\"0\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Zepbound (tirzepatide)\"]}],[\"$\",\"td\",\"1\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"$$1,060\"]}],[\"$\",\"td\",\"2\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Eli Lilly\"]}]]}],[\"$\",\"tr\",\"3\",{\"className\":\"bg-[#FAFAFA]\",\"children\":[[\"$\",\"td\",\"0\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Mounjaro (tirzepatide)\"]}],[\"$\",\"td\",\"1\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"$$1,023\"]}],[\"$\",\"td\",\"2\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Eli Lilly\"]}]]}],[\"$\",\"tr\",\"4\",{\"className\":\"\",\"children\":[[\"$\",\"td\",\"0\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Retatrutide (est.)\"]}],[\"$\",\"td\",\"1\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"$$1,000 to $1,200\"]}],\"$L52\"]}]]}]]}]}]}],\"$L53\"]}]}]]}],\"$L54\",\"$L55\"]}]]}],false]}]\n"])

self.__next_f.push([1,"30:[\"$\",\"div\",\"6\",{\"children\":[[\"$\",\"div\",null,{\"className\":\"mb-10\",\"children\":[[\"$\",\"h2\",null,{\"id\":\"what-should-you-do-while-waiting-for-retatrutide\",\"className\":\"text-2xl font-bold text-[#111] mb-4\",\"children\":\"What Should You Do While Waiting for Retatrutide?\"}],[\"$\",\"div\",null,{\"className\":\"mb-6\",\"children\":[\"$\",\"div\",null,{\"className\":\"space-y-4\",\"children\":[[\"$\",\"p\",\"0\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"The 18 to 24 months between now and retatrutide availability is not wasted time. You have options that work today.\"]}]]}]}],[\"$\",\"div\",null,{\"className\":\"space-y-4 mt-4\",\"children\":[[\"$\",\"div\",\"0\",{\"className\":\"bg-[#F8F8F8] border-l-4 border-[#1526C9] p-5 rounded-r-xl\",\"children\":[[\"$\",\"h3\",null,{\"id\":\"consider-currently-available-medications\",\"className\":\"text-lg font-bold text-[#111] mb-2\",\"children\":\"Consider Currently Available Medications\"}],[\"$\",\"div\",null,{\"className\":\"text-sm\",\"children\":[\"$\",\"div\",null,{\"className\":\"space-y-4\",\"children\":[[\"$\",\"p\",\"0\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Two effective weight loss drugs are available by prescription right now. \",[\"$\",\"$L10\",\"73\",{\"href\":\"/peptides/tirzepatide\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"Tirzepatide\"}],\" (sold as Zepbound for weight loss) targets two of the three receptors that retatrutide hits and produces about 22.5% body weight loss. \",[\"$\",\"$L10\",\"245\",{\"href\":\"/peptides/semaglutide\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"Semaglutide\"}],\" (sold as Wegovy for weight loss) targets one receptor and produces about 15% loss.\"]}],[\"$\",\"p\",\"1\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Starting one of these medications today does not prevent you from switching to retatrutide later. Both tirzepatide and retatrutide are made by Eli Lilly, and the transition would involve a standard dose titration protocol. See our \",[\"$\",\"$L10\",\"231\",{\"href\":\"/blog/retatrutide-dosage-guide\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"retatrutide dosage guide\"}],\" for how titration works. For guidance on transitioning between GLP-1 drugs, see \",[\"$\",\"$L10\",\"370\",{\"href\":\"/blog/semaglutide-to-tirzepatide-switching\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"semaglutide to tirzepatide switching\"}],\".\"]}],[\"$\",\"p\",\"2\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Your doctor can help determine which option fits your medical history, insurance coverage, and goals. If cost is a barrier, manufacturer savings cards can reduce Zepbound to $25 per month for eligible patients. For injection technique, see \",[\"$\",\"$L10\",\"240\",{\"href\":\"/blog/how-to-inject-tirzepatide\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"how to inject tirzepatide\"}],\".\"]}]]}]}]]}],[\"$\",\"div\",\"1\",{\"className\":\"bg-[#F8F8F8] border-l-4 border-[#1526C9] p-5 rounded-r-xl\",\"children\":[[\"$\",\"h3\",null,{\"id\":\"explore-clinical-trial-enrollment\",\"className\":\"text-lg font-bold text-[#111] mb-2\",\"children\":\"Explore Clinical Trial Enrollment\"}],[\"$\",\"div\",null,{\"className\":\"text-sm\",\"children\":[\"$\",\"div\",null,{\"className\":\"space-y-4\",\"children\":[[\"$\",\"p\",\"0\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Two TRIUMPH trials are still recruiting as of March 2026. The maintenance trial (NCT06859268) tests whether patients can reduce their retatrutide dose after achieving significant weight loss. The new enrollment trial (NCT07232719) has 250 spots for adults with obesity or overweight.\"]}],[\"$\",\"p\",\"1\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Search for open trials at ClinicalTrials.gov or trials.lilly.com. Be prepared to provide your BMI, medical history, and current medications during the screening process. If your nearest trial site is far away, some trials cover travel expenses. Ask the study coordinator when you call.\"]}]]}]}]]}],\"$L56\"]}]]}],false]}]\n"])

self.__next_f.push([1,"31:[\"$\",\"div\",\"7\",{\"children\":[[\"$\",\"div\",null,{\"className\":\"mb-10\",\"children\":[[\"$\",\"h2\",null,{\"id\":\"what-could-delay-or-accelerate-the-timeline\",\"className\":\"text-2xl font-bold text-[#111] mb-4\",\"children\":\"What Could Delay or Accelerate the Timeline?\"}],[\"$\",\"div\",null,{\"className\":\"mb-6\",\"children\":[\"$\",\"div\",null,{\"className\":\"space-y-4\",\"children\":[[\"$\",\"p\",\"0\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"The mid-2027 approval estimate is based on current trajectory. Several factors could shift it in either direction.\"]}]]}]}],[\"$\",\"div\",null,{\"className\":\"space-y-4 mt-4\",\"children\":[[\"$\",\"div\",\"0\",{\"className\":\"bg-[#F8F8F8] border-l-4 border-[#1526C9] p-5 rounded-r-xl\",\"children\":[[\"$\",\"h3\",null,{\"id\":\"factors-that-could-speed-things-up\",\"className\":\"text-lg font-bold text-[#111] mb-2\",\"children\":\"Factors That Could Speed Things Up\"}],[\"$\",\"div\",null,{\"className\":\"text-sm\",\"children\":[\"$\",\"div\",null,{\"className\":\"space-y-4\",\"children\":[[\"$\",\"p\",\"0\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[[\"$\",\"strong\",\"0\",{\"className\":\"text-[#111] font-semibold\",\"children\":[\"Breakthrough Therapy Designation.\"]}],\" If the FDA grants this designation (which it has not yet), Lilly would receive more intensive FDA guidance and a potentially faster review. The 28.7% weight loss and 82% liver fat reduction could justify this designation, particularly for MASLD, which currently has limited treatment options.\"]}],[\"$\",\"p\",\"1\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[[\"$\",\"strong\",\"0\",{\"className\":\"text-[#111] font-semibold\",\"children\":[\"Positive TRIUMPH-1 and TRIUMPH-2 results.\"]}],\" If both pivotal trials deliver results as strong as or stronger than TRIUMPH-4, Lilly could submit the NDA as early as Q3 2026 rather than Q4, shaving 1 to 3 months off the timeline.\"]}],[\"$\",\"p\",\"2\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[[\"$\",\"strong\",\"0\",{\"className\":\"text-[#111] font-semibold\",\"children\":[\"Rolling submission.\"]}],\" The FDA sometimes allows companies to submit sections of the NDA as they become ready, rather than waiting for the complete application. This can save 2 to 4 months. Lilly used this approach with tirzepatide.\"]}]]}]}]]}],[\"$\",\"div\",\"1\",{\"className\":\"bg-[#F8F8F8] border-l-4 border-[#1526C9] p-5 rounded-r-xl\",\"children\":[[\"$\",\"h3\",null,{\"id\":\"factors-that-could-slow-things-down\",\"className\":\"text-lg font-bold text-[#111] mb-2\",\"children\":\"Factors That Could Slow Things Down\"}],[\"$\",\"div\",null,{\"className\":\"text-sm\",\"children\":[\"$\",\"div\",null,{\"className\":\"space-y-4\",\"children\":[[\"$\",\"p\",\"0\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[[\"$\",\"strong\",\"0\",{\"className\":\"text-[#111] font-semibold\",\"children\":[\"Safety signals in larger trials.\"]}],\" If TRIUMPH-1 or TRIUMPH-2 reveal a new safety concern not seen in smaller trials, the FDA could require additional studies. The dysesthesia signal from TRIUMPH-4 is already on the agency's radar. If the rate or severity increases in larger populations, it could prompt a complete response letter.\"]}],[\"$\",\"p\",\"1\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[[\"$\",\"strong\",\"0\",{\"className\":\"text-[#111] font-semibold\",\"children\":[\"Manufacturing delays.\"]}],\" Peptide manufacturing at pharmaceutical scale is technically demanding. If Lilly encounters production problems, it could delay the launch even after approval. The company's $4 billion manufacturing investment is designed to prevent this, but technical issues can still arise.\"]}],[\"$\",\"p\",\"2\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[[\"$\",\"strong\",\"0\",{\"className\":\"text-[#111] font-semibold\",\"children\":[\"Regulatory environment changes.\"]}],\" The FDA's approach to obesity drugs has been evolving. A change in FDA leadership, new safety requirements, or shifts in regulatory philosophy could add review time. The current FDA commissioner has been supportive of obesity drug development, but political changes are unpredictable.\"]}],\"$L57\"]}]}]]}]]}]]}],false]}]\n"])

self.__next_f.push([1,"32:[\"$\",\"div\",\"8\",{\"children\":[[\"$\",\"div\",null,{\"className\":\"mb-10\",\"children\":[[\"$\",\"h2\",null,{\"id\":\"international-availability-when-will-other-countries-approve-retatrutide\",\"className\":\"text-2xl font-bold text-[#111] mb-4\",\"children\":\"International Availability: When Will Other Countries Approve Retatrutide?\"}],[\"$\",\"div\",null,{\"className\":\"mb-6\",\"children\":[\"$\",\"div\",null,{\"className\":\"space-y-4\",\"children\":[[\"$\",\"p\",\"0\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"FDA approval does not automatically make retatrutide available worldwide. Each country or region has its own regulatory process.\"]}]]}]}],[\"$\",\"div\",null,{\"className\":\"space-y-4 mt-4\",\"children\":[[\"$\",\"div\",\"0\",{\"className\":\"bg-[#F8F8F8] border-l-4 border-[#1526C9] p-5 rounded-r-xl\",\"children\":[[\"$\",\"h3\",null,{\"id\":\"european-medicines-agency-ema\",\"className\":\"text-lg font-bold text-[#111] mb-2\",\"children\":\"European Medicines Agency (EMA)\"}],[\"$\",\"div\",null,{\"className\":\"text-sm\",\"children\":[\"$\",\"div\",null,{\"className\":\"space-y-4\",\"children\":[[\"$\",\"p\",\"0\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Eli Lilly typically files for European approval (through the EMA's centralized procedure) around the same time as the FDA submission, sometimes within a few months. The EMA review process takes approximately 12 to 15 months, longer than the FDA. If Lilly files with both agencies in late 2026, European approval could come in early to mid-2028.\"]}],[\"$\",\"p\",\"1\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"However, individual European countries then negotiate pricing and reimbursement, which adds another 6 to 18 months before the drug is actually available at pharmacies in each country. UK approval through the MHRA may come separately and could be faster since Brexit allowed the UK to conduct independent reviews.\"]}]]}]}]]}],[\"$\",\"div\",\"1\",{\"className\":\"bg-[#F8F8F8] border-l-4 border-[#1526C9] p-5 rounded-r-xl\",\"children\":[[\"$\",\"h3\",null,{\"id\":\"other-markets\",\"className\":\"text-lg font-bold text-[#111] mb-2\",\"children\":\"Other Markets\"}],[\"$\",\"div\",null,{\"className\":\"text-sm\",\"children\":[\"$\",\"div\",null,{\"className\":\"space-y-4\",\"children\":[[\"$\",\"p\",\"0\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Japan, Australia, Canada, and several other countries have their own approval pathways. Japan's PMDA often requires Japan-specific clinical data, which could delay approval there. Australia's TGA and Canada's Health Canada sometimes rely on FDA or EMA reviews to expedite their own processes.\"]}],[\"$\",\"p\",\"1\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"The bottom line: if you are outside the United States, expect retatrutide availability 6 to 18 months after FDA approval, depending on your country's regulatory timeline and Lilly's submission strategy.\"]}]]}]}]]}]]}]]}],false]}]\n"])

self.__next_f.push([1,"33:[\"$\",\"div\",\"9\",{\"children\":[[\"$\",\"div\",null,{\"className\":\"mb-10\",\"children\":[[\"$\",\"h2\",null,{\"id\":\"how-retatrutide-fits-into-the-weight-loss-drug-pipeline\",\"className\":\"text-2xl font-bold text-[#111] mb-4\",\"children\":\"How Retatrutide Fits Into the Weight Loss Drug Pipeline\"}],[\"$\",\"div\",null,{\"className\":\"mb-6\",\"children\":[\"$\",\"div\",null,{\"className\":\"space-y-4\",\"children\":[[\"$\",\"p\",\"0\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Retatrutide is not the only next-generation weight loss drug in development. Several competitors are pursuing similar or alternative approaches, and the competitive landscape could influence pricing, availability, and insurance coverage.\"]}]]}]}],[\"$\",\"div\",null,{\"className\":\"space-y-4 mt-4\",\"children\":[[\"$\",\"div\",\"0\",{\"className\":\"bg-[#F8F8F8] border-l-4 border-[#1526C9] p-5 rounded-r-xl\",\"children\":[[\"$\",\"h3\",null,{\"id\":\"orforglipron-eli-lilly-the-oral-option\",\"className\":\"text-lg font-bold text-[#111] mb-2\",\"children\":\"Orforglipron (Eli Lilly): The Oral Option\"}],[\"$\",\"div\",null,{\"className\":\"text-sm\",\"children\":[\"$\",\"div\",null,{\"className\":\"space-y-4\",\"children\":[[\"$\",\"p\",\"0\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Eli Lilly is also developing orforglipron, an oral (pill) GLP-1 agonist. In Phase 3 trials, orforglipron produced approximately 12 to 14% weight loss. That is less than injectable retatrutide but comes in a pill format that many patients prefer over weekly injections. Orforglipron is on a similar timeline to retatrutide, with potential approval in 2027 or 2028.\"]}],[\"$\",\"p\",\"1\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Lilly may position retatrutide as the maximum-efficacy injectable option and orforglipron as the more convenient oral option, giving doctors and patients a choice within Lilly's own portfolio.\"]}]]}]}]]}],[\"$\",\"div\",\"1\",{\"className\":\"bg-[#F8F8F8] border-l-4 border-[#1526C9] p-5 rounded-r-xl\",\"children\":[[\"$\",\"h3\",null,{\"id\":\"amycretin-novo-nordisk-the-dual-approach\",\"className\":\"text-lg font-bold text-[#111] mb-2\",\"children\":\"Amycretin (Novo Nordisk): The Dual Approach\"}],[\"$\",\"div\",null,{\"className\":\"text-sm\",\"children\":[\"$\",\"div\",null,{\"className\":\"space-y-4\",\"children\":[[\"$\",\"p\",\"0\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Novo Nordisk, the maker of Ozempic and Wegovy, is developing amycretin, a dual GLP-1 and amylin agonist. Early data showed approximately 22% weight loss in 36 weeks, which extrapolates to potentially 25% or more at 68 weeks. This positions amycretin as a direct competitor to retatrutide, likely reaching market around the same time.\"]}],[\"$\",\"p\",\"1\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"The existence of multiple competitors is actually good for patients. Competition typically drives prices down, expands insurance coverage, and gives doctors more options to match individual patient needs. For a perspective on existing drug comparisons, see \",[\"$\",\"$L10\",\"257\",{\"href\":\"/blog/retatrutide-vs-tirzepatide\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"retatrutide vs tirzepatide\"}],\".\"]}]]}]}]]}],[\"$\",\"div\",\"2\",{\"className\":\"bg-[#F8F8F8] border-l-4 border-[#1526C9] p-5 rounded-r-xl\",\"children\":[[\"$\",\"h3\",null,{\"id\":\"survodutide-boehringer-ingelheim-another-glucagon-approach\",\"className\":\"text-lg font-bold text-[#111] mb-2\",\"children\":\"Survodutide (Boehringer Ingelheim): Another Glucagon Approach\"}],[\"$\",\"div\",null,{\"className\":\"text-sm\",\"children\":[\"$\",\"div\",null,{\"className\":\"space-y-4\",\"children\":[[\"$\",\"p\",\"0\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Survodutide is a dual GLP-1 and glucagon agonist (it skips GIP). Phase 2 results showed approximately 19% weight loss at 46 weeks. This drug targets the same glucagon receptor as retatrutide but without the GIP component. If survodutide reaches market before retatrutide, it could provide early real-world evidence on glucagon receptor safety, which would benefit the retatrutide review process.\"]}]]}]}]]}]]}]]}],false]}]\n"])

self.__next_f.push([1,"34:[\"$\",\"div\",\"10\",{\"children\":[[\"$\",\"div\",null,{\"className\":\"mb-10\",\"children\":[[\"$\",\"h2\",null,{\"id\":\"key-dates-to-watch-in-2026-and-2027\",\"className\":\"text-2xl font-bold text-[#111] mb-4\",\"children\":\"Key Dates to Watch in 2026 and 2027\"}],[\"$\",\"div\",null,{\"className\":\"mb-6\",\"children\":[\"$\",\"div\",null,{\"className\":\"space-y-4\",\"children\":[[\"$\",\"p\",\"0\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"If you are tracking retatrutide's progress toward availability, these are the dates and events that matter most.\"]}],[\"$\",\"div\",\"1\",{\"children\":[\"$\",\"div\",null,{\"className\":\"overflow-x-auto rounded-xl border border-gray-200\",\"children\":[\"$\",\"table\",null,{\"className\":\"w-full text-sm\",\"children\":[[\"$\",\"thead\",null,{\"children\":[\"$\",\"tr\",null,{\"className\":\"bg-[#F8F8F8]\",\"children\":[[\"$\",\"th\",\"0\",{\"className\":\"text-left text-[#111] font-semibold px-4 py-3 border-b border-gray-200\",\"children\":[\"When\"]}],[\"$\",\"th\",\"1\",{\"className\":\"text-left text-[#111] font-semibold px-4 py-3 border-b border-gray-200\",\"children\":[\"What to Watch For\"]}]]}]}],[\"$\",\"tbody\",null,{\"children\":[[\"$\",\"tr\",\"0\",{\"className\":\"\",\"children\":[[\"$\",\"td\",\"0\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Q2 2026\"]}],[\"$\",\"td\",\"1\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"TRIUMPH-1 and TRIUMPH-2 top-line results\"]}]]}],[\"$\",\"tr\",\"1\",{\"className\":\"bg-[#FAFAFA]\",\"children\":[[\"$\",\"td\",\"0\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Q3 2026\"]}],[\"$\",\"td\",\"1\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Lilly earnings call commentary on NDA timeline\"]}]]}],[\"$\",\"tr\",\"2\",{\"className\":\"\",\"children\":[[\"$\",\"td\",\"0\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Q4 2026\"]}],[\"$\",\"td\",\"1\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Potential NDA submission to FDA\"]}]]}],[\"$\",\"tr\",\"3\",{\"className\":\"bg-[#FAFAFA]\",\"children\":[[\"$\",\"td\",\"0\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"December 2026\"]}],[\"$\",\"td\",\"1\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Head-to-head vs tirzepatide results\"]}]]}],[\"$\",\"tr\",\"4\",{\"className\":\"\",\"children\":[[\"$\",\"td\",\"0\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Q1 2027\"]}],[\"$\",\"td\",\"1\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"FDA acceptance of NDA, PDUFA date announced\"]}]]}],[\"$\",\"tr\",\"5\",{\"className\":\"bg-[#FAFAFA]\",\"children\":[[\"$\",\"td\",\"0\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Q2-Q3 2027\"]}],[\"$\",\"td\",\"1\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Potential advisory committee meeting\"]}]]}],[\"$\",\"tr\",\"6\",{\"className\":\"\",\"children\":[[\"$\",\"td\",\"0\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Mid to Late 2027\"]}],[\"$\",\"td\",\"1\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"FDA approval decision\"]}]]}],[\"$\",\"tr\",\"7\",{\"className\":\"bg-[#FAFAFA]\",\"children\":[[\"$\",\"td\",\"0\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Late 2027 to Q1 2028\"]}],[\"$\",\"td\",\"1\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Commercial availability at pharmacies\"]}]]}]]}]]}]}]}],[\"$\",\"p\",\"2\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Set up free alerts on \",[\"$\",\"a\",\"22\",{\"href\":\"https://clinicaltrials.gov\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"ClinicalTrials.gov\"}],\" for \\\"retatrutide\\\" to be notified of trial updates. Follow Eli Lilly's \",[\"$\",\"a\",\"141\",{\"href\":\"https://investor.lilly.com\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"investor relations page\"}],\" for press releases. We will update this article as each milestone is reached.\"]}],[\"$\",\"p\",\"3\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"For the current regulatory landscape affecting all peptides, see \",\"$L58\",\". For dosing reference across available peptides, see the \",\"$L59\",\". For reconstitution guidance, see the \",\"$L5a\",\".\"]}]]}]}],\"$L5b\"]}],false]}]\n"])

self.__next_f.push([1,"35:[\"$\",\"div\",null,{\"className\":\"mb-10\",\"children\":[[\"$\",\"h2\",null,{\"id\":\"faq\",\"className\":\"text-2xl font-bold text-[#111] mb-6\",\"children\":\"Frequently Asked Questions\"}],[\"$\",\"div\",null,{\"className\":\"space-y-4\",\"children\":[[\"$\",\"details\",\"0\",{\"className\":\"group bg-[#F8F8F8] border border-gray-200 rounded-2xl overflow-hidden\",\"children\":[[\"$\",\"summary\",null,{\"className\":\"flex items-center justify-between p-5 cursor-pointer list-none\",\"children\":[[\"$\",\"span\",null,{\"className\":\"text-[#111] font-semibold text-sm pr-4\",\"children\":\"When will retatrutide be available at pharmacies?\"}],[\"$\",\"svg\",null,{\"className\":\"w-5 h-5 text-[#999] flex-shrink-0 transition-transform group-open:rotate-180\",\"fill\":\"none\",\"viewBox\":\"0 0 24 24\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"children\":[\"$\",\"path\",null,{\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"d\":\"M19 9l-7 7-7-7\"}]}]]}],[\"$\",\"div\",null,{\"className\":\"px-5 pb-5 -mt-1 text-sm\",\"children\":[\"$\",\"div\",null,{\"className\":\"space-y-4\",\"children\":[[\"$\",\"p\",\"0\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"The most realistic estimate is late 2027 to early 2028. Eli Lilly needs to finish Phase 3 trials (mid-2026), submit a New Drug Application (late 2026), and wait for the FDA to review it (6 to 10 months). Best case with Priority Review is Q3 2027. Standard Review pushes availability to Q4 2027 or Q1 2028.\"]}]]}]}]]}],[\"$\",\"details\",\"1\",{\"className\":\"group bg-[#F8F8F8] border border-gray-200 rounded-2xl overflow-hidden\",\"children\":[[\"$\",\"summary\",null,{\"className\":\"flex items-center justify-between p-5 cursor-pointer list-none\",\"children\":[[\"$\",\"span\",null,{\"className\":\"text-[#111] font-semibold text-sm pr-4\",\"children\":\"Is retatrutide FDA-approved?\"}],[\"$\",\"svg\",null,{\"className\":\"w-5 h-5 text-[#999] flex-shrink-0 transition-transform group-open:rotate-180\",\"fill\":\"none\",\"viewBox\":\"0 0 24 24\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"children\":[\"$\",\"path\",null,{\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"d\":\"M19 9l-7 7-7-7\"}]}]]}],[\"$\",\"div\",null,{\"className\":\"px-5 pb-5 -mt-1 text-sm\",\"children\":[\"$\",\"div\",null,{\"className\":\"space-y-4\",\"children\":[[\"$\",\"p\",\"0\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"No. As of March 2026, retatrutide has not been approved by the FDA or any other regulatory agency worldwide. It is in Phase 3 clinical trials under Eli Lilly's TRIUMPH program. No doctor can prescribe it and no pharmacy can legally fill it. The only legal access is through clinical trials or, in extreme cases, expanded access.\"]}]]}]}]]}],[\"$\",\"details\",\"2\",{\"className\":\"group bg-[#F8F8F8] border border-gray-200 rounded-2xl overflow-hidden\",\"children\":[[\"$\",\"summary\",null,{\"className\":\"flex items-center justify-between p-5 cursor-pointer list-none\",\"children\":[[\"$\",\"span\",null,{\"className\":\"text-[#111] font-semibold text-sm pr-4\",\"children\":\"How much weight can you lose on retatrutide?\"}],[\"$\",\"svg\",null,{\"className\":\"w-5 h-5 text-[#999] flex-shrink-0 transition-transform group-open:rotate-180\",\"fill\":\"none\",\"viewBox\":\"0 0 24 24\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"children\":[\"$\",\"path\",null,{\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"d\":\"M19 9l-7 7-7-7\"}]}]]}],[\"$\",\"div\",null,{\"className\":\"px-5 pb-5 -mt-1 text-sm\",\"children\":[\"$\",\"div\",null,{\"className\":\"space-y-4\",\"children\":[[\"$\",\"p\",\"0\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"In the Phase 3 TRIUMPH-4 trial, participants on the highest dose (12 mg) lost an average of 28.7% of their body weight over 68 weeks. That translates to roughly 71 pounds from a 249-pound starting weight. Participants were still losing weight when the trial ended, suggesting the final number could be higher with longer use.\"]}]]}]}]]}],[\"$\",\"details\",\"3\",{\"className\":\"group bg-[#F8F8F8] border border-gray-200 rounded-2xl overflow-hidden\",\"children\":[[\"$\",\"summary\",null,{\"className\":\"flex items-center justify-between p-5 cursor-pointer list-none\",\"children\":[\"$L5c\",\"$L5d\"]}],\"$L5e\"]}],\"$L5f\",\"$L60\",\"$L61\",\"$L62\"]}]]}]\n"])

self.__next_f.push([1,"36:[\"$\",\"div\",null,{\"className\":\"mb-10 bg-[#F8F8F8] border border-gray-200 rounded-2xl p-6\",\"children\":[[\"$\",\"h2\",null,{\"id\":\"bottom-line\",\"className\":\"text-xl font-bold text-[#111] mb-3\",\"children\":\"The Bottom Line\"}],[\"$\",\"div\",null,{\"className\":\"space-y-4\",\"children\":[[\"$\",\"p\",\"0\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Retatrutide is the most powerful weight loss drug in development. The 28.7% body weight loss recorded in Phase 3 exceeds every other drug on the market or in testing. But power without availability is just a number on a research poster.\"]}],[\"$\",\"p\",\"1\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"The realistic timeline: pivotal trial results by mid-2026, NDA submission by late 2026, FDA decision by mid to late 2027, and pharmacy availability by late 2027 or early 2028. That is 18 to 24 months from now.\"]}],[\"$\",\"p\",\"2\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Your options today are clear. If you qualify, enroll in a clinical trial for free pharmaceutical-grade access. If you need weight management now, \",[\"$\",\"$L10\",\"146\",{\"href\":\"/peptides/tirzepatide\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"tirzepatide\"}],\" (Zepbound) and \",[\"$\",\"$L10\",\"198\",{\"href\":\"/peptides/semaglutide\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"semaglutide\"}],\" (Wegovy) are FDA-approved, available by prescription, and produce meaningful results (22.5% and 15% weight loss, respectively). Starting one now does not prevent switching to retatrutide later. For a side-by-side, see \",[\"$\",\"$L10\",\"453\",{\"href\":\"/blog/retatrutide-vs-tirzepatide\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"retatrutide vs tirzepatide\"}],\".\"]}],[\"$\",\"p\",\"3\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Avoid unregulated research peptides unless you fully understand the risks: no pharmaceutical-quality standards, no FDA oversight, and documented contamination in seized samples. For the regulatory picture, see \",[\"$\",\"$L10\",\"210\",{\"href\":\"/blog/fda-peptide-crackdown-2026\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"FDA peptide crackdown 2026\"}],\".\"]}],[\"$\",\"p\",\"4\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"We will update this article as each milestone is reached. Key dates: TRIUMPH-1 and TRIUMPH-2 results (mid-2026), head-to-head vs tirzepatide (December 2026), and any NDA filing announcement from Eli Lilly.\"]}],[\"$\",\"p\",\"5\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[[\"$\",\"strong\",\"0\",{\"className\":\"text-[#111] font-semibold\",\"children\":[\"Related Articles:\"]}],\"\\n- \",[\"$\",\"$L10\",\"24\",{\"href\":\"/blog/retatrutide\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"Retatrutide: Complete Guide\"}],\"\\n- \",[\"$\",\"$L10\",\"75\",{\"href\":\"/blog/retatrutide-dosage-guide\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"Retatrutide Dosage Guide\"}],\"\\n- \",[\"$\",\"$L10\",\"136\",{\"href\":\"/blog/retatrutide-side-effects\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"Retatrutide Side Effects\"}],\"\\n- \",[\"$\",\"$L10\",\"197\",{\"href\":\"/blog/how-does-retatrutide-work\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"How Does Retatrutide Work\"}],\"\\n- \",[\"$\",\"$L10\",\"260\",{\"href\":\"/blog/retatrutide-how-to-get\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"Retatrutide: How to Get It\"}],\"\\n- \",[\"$\",\"$L10\",\"321\",{\"href\":\"/blog/retatrutide-vs-tirzepatide\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"Retatrutide vs Tirzepatide\"}],\"\\n- \",[\"$\",\"$L10\",\"386\",{\"href\":\"/blog/fda-peptide-crackdown-2026\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"FDA Peptide Crackdown 2026\"}],\"\\n- \",\"$L63\",\"\\n- \",\"$L64\",\"\\n- \",\"$L65\"]}]]}]]}]\n"])

self.__next_f.push([1,"37:[\"$\",\"div\",null,{\"className\":\"border-t border-gray-200 pt-8 mb-10\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"text-lg font-bold text-[#111] mb-4\",\"children\":\"Helpful Tools\"}],[\"$\",\"div\",null,{\"className\":\"grid grid-cols-1 md:grid-cols-3 gap-4\",\"children\":[[\"$\",\"$L10\",\"/tools/retatrutide-dosage-calculator\",{\"href\":\"/tools/retatrutide-dosage-calculator\",\"className\":\"p-4 bg-[#F8F8F8] hover:border-[#1526C9]/30 border border-gray-200 rounded-xl transition-all\",\"children\":[\"$\",\"div\",null,{\"className\":\"font-semibold text-[#111] text-sm\",\"children\":\"Retatrutide Dosage Calculator\"}]}],[\"$\",\"$L10\",\"/tools/peptide-cost-calculator\",{\"href\":\"/tools/peptide-cost-calculator\",\"className\":\"p-4 bg-[#F8F8F8] hover:border-[#1526C9]/30 border border-gray-200 rounded-xl transition-all\",\"children\":[\"$\",\"div\",null,{\"className\":\"font-semibold text-[#111] text-sm\",\"children\":\"Peptide Cost Calculator\"}]}],[\"$\",\"$L10\",\"/tools/peptide-reconstitution-calculator\",{\"href\":\"/tools/peptide-reconstitution-calculator\",\"className\":\"p-4 bg-[#F8F8F8] hover:border-[#1526C9]/30 border border-gray-200 rounded-xl transition-all\",\"children\":[\"$\",\"div\",null,{\"className\":\"font-semibold text-[#111] text-sm\",\"children\":\"Peptide Reconstitution Calculator\"}]}],[\"$\",\"$L10\",\"/tools/peptide-interaction-checker\",{\"href\":\"/tools/peptide-interaction-checker\",\"className\":\"p-4 bg-[#F8F8F8] hover:border-[#1526C9]/30 border border-gray-200 rounded-xl transition-all\",\"children\":[\"$\",\"div\",null,{\"className\":\"font-semibold text-[#111] text-sm\",\"children\":\"Peptide Interaction Checker\"}]}]]}]]}]\n"])

self.__next_f.push([1,"38:[\"$\",\"div\",null,{\"data-print-hide\":true,\"children\":[\"$\",\"div\",null,{\"className\":\"border-t border-gray-200 pt-8 mb-10\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"text-lg font-bold text-[#111] mb-4\",\"children\":\"Related Articles\"}],[\"$\",\"div\",null,{\"className\":\"grid grid-cols-1 md:grid-cols-2 gap-4\",\"children\":[[\"$\",\"$L10\",\"retatrutide\",{\"href\":\"/blog/retatrutide\",\"className\":\"group p-5 bg-[#F8F8F8] hover:border-[#1526C9]/30 border border-gray-200 rounded-xl transition-all\",\"children\":[[\"$\",\"span\",null,{\"className\":\"inline-block text-xs font-semibold px-2.5 py-0.5 rounded-full border mb-2 bg-blue-50 text-[#1526C9] border-blue-200\",\"children\":\"Complete Guides\"}],[\"$\",\"h4\",null,{\"className\":\"text-sm font-semibold text-[#111] group-hover:text-[#1526C9] transition-colors mb-1.5 line-clamp-2\",\"children\":\"Retatrutide: Mechanism \u0026 Trial Results\"}],[\"$\",\"p\",null,{\"className\":\"text-xs text-[#666] line-clamp-2\",\"children\":\"Retatrutide (LY3437943) is a triple agonist weight loss drug by Eli Lilly. 28.7% weight loss in trials, 82% liver fat reduction. Not yet FDA-approved.\"}],[\"$\",\"div\",null,{\"className\":\"flex gap-1.5 mt-2\",\"children\":[[\"$\",\"span\",\"Retatrutide\",{\"className\":\"text-[10px] text-[#999] bg-white px-2 py-0.5 rounded-full border border-gray-200\",\"children\":[\"#\",\"retatrutide\"]}],[\"$\",\"span\",\"Weight Loss\",{\"className\":\"text-[10px] text-[#999] bg-white px-2 py-0.5 rounded-full border border-gray-200\",\"children\":[\"#\",\"weightloss\"]}]]}]]}],[\"$\",\"$L10\",\"retatrutide-how-to-get\",{\"href\":\"/blog/retatrutide-how-to-get\",\"className\":\"group p-5 bg-[#F8F8F8] hover:border-[#1526C9]/30 border border-gray-200 rounded-xl transition-all\",\"children\":[[\"$\",\"span\",null,{\"className\":\"inline-block text-xs font-semibold px-2.5 py-0.5 rounded-full border mb-2 bg-cyan-50 text-cyan-600 border-cyan-200\",\"children\":\"Access Guides\"}],[\"$\",\"h4\",null,{\"className\":\"text-sm font-semibold text-[#111] group-hover:text-[#1526C9] transition-colors mb-1.5 line-clamp-2\",\"children\":\"How to Get Retatrutide in 2026\"}],[\"$\",\"p\",null,{\"className\":\"text-xs text-[#666] line-clamp-2\",\"children\":\"How to access retatrutide in 2026: clinical trial enrollment, compounding pharmacy status, FDA approval timeline (est. 2027). Updated March 2026.\"}],[\"$\",\"div\",null,{\"className\":\"flex gap-1.5 mt-2\",\"children\":[[\"$\",\"span\",\"Retatrutide\",{\"className\":\"text-[10px] text-[#999] bg-white px-2 py-0.5 rounded-full border border-gray-200\",\"children\":[\"#\",\"retatrutide\"]}],[\"$\",\"span\",\"Clinical Trials\",{\"className\":\"text-[10px] text-[#999] bg-white px-2 py-0.5 rounded-full border border-gray-200\",\"children\":[\"#\",\"clinicaltrials\"]}]]}]]}],[\"$\",\"$L10\",\"how-does-retatrutide-work\",{\"href\":\"/blog/how-does-retatrutide-work\",\"className\":\"group p-5 bg-[#F8F8F8] hover:border-[#1526C9]/30 border border-gray-200 rounded-xl transition-all\",\"children\":[[\"$\",\"span\",null,{\"className\":\"inline-block text-xs font-semibold px-2.5 py-0.5 rounded-full border mb-2 bg-violet-50 text-violet-600 border-violet-200\",\"children\":\"Mechanism Guides\"}],[\"$\",\"h4\",null,{\"className\":\"text-sm font-semibold text-[#111] group-hover:text-[#1526C9] transition-colors mb-1.5 line-clamp-2\",\"children\":\"How Does Retatrutide Work?\"}],[\"$\",\"p\",null,{\"className\":\"text-xs text-[#666] line-clamp-2\",\"children\":\"Retatrutide activates 3 receptors (GLP-1, GIP, glucagon) to reduce appetite, improve metabolism, and burn fat. 28.7% weight loss in trials.\"}],[\"$\",\"div\",null,{\"className\":\"flex gap-1.5 mt-2\",\"children\":[[\"$\",\"span\",\"Retatrutide\",{\"className\":\"text-[10px] text-[#999] bg-white px-2 py-0.5 rounded-full border border-gray-200\",\"children\":[\"#\",\"retatrutide\"]}],[\"$\",\"span\",\"Mechanism of Action\",{\"className\":\"text-[10px] text-[#999] bg-white px-2 py-0.5 rounded-full border border-gray-200\",\"children\":[\"#\",\"mechanismofaction\"]}]]}]]}],[\"$\",\"$L10\",\"retatrutide-side-effects\",{\"href\":\"/blog/retatrutide-side-effects\",\"className\":\"group p-5 bg-[#F8F8F8] hover:border-[#1526C9]/30 border border-gray-200 rounded-xl transition-all\",\"children\":[\"$L66\",\"$L67\",\"$L68\",\"$L69\"]}]]}]]}]}]\n"])

self.__next_f.push([1,"39:[\"$\",\"div\",null,{\"className\":\"text-center\",\"data-print-hide\":true,\"children\":[\"$\",\"$L10\",null,{\"href\":\"/blog\",\"className\":\"text-[#1526C9] hover:text-[#0f1d9a] font-semibold inline-flex items-center gap-2 transition-colors\",\"children\":\"← Back to Blog\"}]}]\n"])

self.__next_f.push([1,"3a:[\"$\",\"td\",\"2\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"2,300\"]}]\n3b:[\"$\",\"td\",\"3\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[[\"$\",\"a\",\"0\",{\"href\":\"https://clinicaltrials.gov/study/NCT05929066\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"NCT05929066\"}]]}]\n3c:[\"$\",\"td\",\"4\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Active, results expected mid-2026\"]}]\n3d:[\"$\",\"tr\",\"1\",{\"className\":\"bg-[#FAFAFA]\",\"children\":[[\"$\",\"td\",\"0\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"TRIUMPH-2\"]}],[\"$\",\"td\",\"1\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Type 2 diabetes + obesity\"]}],[\"$\",\"td\",\"2\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"1,000\"]}],[\"$\",\"td\",\"3\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[[\"$\",\"a\",\"0\",{\"href\":\"https://clinicaltrials.gov/study/NCT05929079\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"NCT05929079\"}]]}],[\"$\",\"td\",\"4\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Active, results expected mid-2026\"]}]]}]\n3e:[\"$\",\"tr\",\"2\",{\"className\":\"\",\"children\":[[\"$\",\"td\",\"0\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"TRIUMPH-3\"]}],[\"$\",\"td\",\"1\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Cardiovascular outcomes\"]}],[\"$\",\"td\",\"2\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"1,800\"]}],[\"$\",\"td\",\"3\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[[\"$\",\"a\",\"0\",{\"href\":\"https://clinicaltrials.gov/study/NCT05882045\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"NCT05882045\"}]]}],[\"$\",\"td\",\"4\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Active, long-term\"]}]]}]\n3f:[\"$\",\"tr\",\"3\",{\"className\":\"bg-[#FAFAFA]\",\"children\":[[\"$\",\"td\",\"0\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"TRIUMPH-4\"]}],[\"$\",\"td\",\"1\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Knee osteoarthritis\"]}],[\"$\",\"td\",\"2\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"445\"]}],[\"$\",\"td\",\"3\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[[\"$\",\"a\",\"0\",{\"href\":\"https://clinicaltrials.gov/study/NCT05931367\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"NCT05931367\"}]]}],[\"$\",\"td\",\"4\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Completed (Dec 2025)\"]}]]}]\n40:[\"$\",\"tr\",\"4\",{\"className\":\"\",\"children\":[[\"$\",\"td\",\"0\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"TRIUMPH-Outcomes\"]}],[\"$\",\"td\",\"1\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"CV/kidney long-term\"]}],[\"$\",\"td\",\"2\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"TBD\"]}],[\"$\",\"td\",\"3\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[[\"$\",\"a\",\"0\",{\"href\":\"https://clinicaltrials.gov/study/NCT06383390\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"NCT06383390\"}]]}],[\"$\",\"td\",\"4\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Enrolling\"]}]]}]\n41:[\"$\",\"tr\",\"5\",{\"className\":\"bg-[#FAFAFA]\",\"children\":[[\"$\",\"td\",\"0\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Head-to-head\"]}],[\"$\",\"td\",\"1\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Retatrutide vs tirzepatide\"]}],[\"$\",\"td\",\"2\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"800\"]}],[\"$\",\"td\",\"3\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[[\"$\""])

self.__next_f.push([1,",\"a\",\"0\",{\"href\":\"https://clinicaltrials.gov/study/NCT06662383\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"NCT06662383\"}]]}],[\"$\",\"td\",\"4\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Active, results expected Dec 2026\"]}]]}]\n42:[\"$\",\"tr\",\"6\",{\"className\":\"\",\"children\":[[\"$\",\"td\",\"0\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Maintenance\"]}],[\"$\",\"td\",\"1\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Dose reduction\"]}],[\"$\",\"td\",\"2\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"TBD\"]}],[\"$\",\"td\",\"3\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[[\"$\",\"a\",\"0\",{\"href\":\"https://clinicaltrials.gov/study/NCT06859268\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"NCT06859268\"}]]}],[\"$\",\"td\",\"4\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Recruiting\"]}]]}]\n43:[\"$\",\"tr\",\"7\",{\"className\":\"bg-[#FAFAFA]\",\"children\":[[\"$\",\"td\",\"0\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"New enrollment\"]}],[\"$\",\"td\",\"1\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Obesity/overweight\"]}],[\"$\",\"td\",\"2\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"250\"]}],[\"$\",\"td\",\"3\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[[\"$\",\"a\",\"0\",{\"href\":\"https://clinicaltrials.gov/study/NCT07232719\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"NCT07232719\"}]]}],[\"$\",\"td\",\"4\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Recruiting\"]}]]}]\n44:[\"$\",\"p\",\"2\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"TRIUMPH-1 and TRIUMPH-2 are the pivotal trials. \\\"Pivotal\\\" means the FDA considers their results the primary evidence for an approval decision. Both are expected to report results by mid-2026. Without positive results from these two trials, the entire timeline shifts later. With positive results, Eli Lilly can begin assembling the application immediately.\"]}]\n45:[\"$\",\"p\",\"3\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"The head-to-head trial against \",[\"$\",\"$L10\",\"31\",{\"href\":\"/peptides/tirzepatide\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"tirzepatide\"}],\" (NCT06662383) is particularly interesting. This is the first trial directly comparing retatrutide and tirzepatide in 800 patients under identical conditions. Results are expected in December 2026. For an existing comparison based on separate trials, see our \",[\"$\",\"$L10\",\"326\",{\"href\":\"/blog/retatrutide-vs-tirzepatide\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"retatrutide vs tirzepatide\"}],\" analysis.\"]}]\n"])

self.__next_f.push([1,"46:[\"$\",\"div\",\"1\",{\"className\":\"bg-[#F8F8F8] border-l-4 border-[#1526C9] p-5 rounded-r-xl\",\"children\":[[\"$\",\"h3\",null,{\"id\":\"what-the-phase-2-data-already-proved\",\"className\":\"text-lg font-bold text-[#111] mb-2\",\"children\":\"What the Phase 2 Data Already Proved\"}],[\"$\",\"div\",null,{\"className\":\"text-sm\",\"children\":[\"$\",\"div\",null,{\"className\":\"space-y-4\",\"children\":[[\"$\",\"p\",\"0\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"The Phase 2 trial published in the New England Journal of Medicine in June 2023 was what put retatrutide on the map. In that trial, 338 adults with obesity received weekly injections for 48 weeks. People on the highest dose (12 mg) lost 24.2% of their body weight. Some participants lost over 30% (\",[\"$\",\"a\",\"298\",{\"href\":\"https://pubmed.ncbi.nlm.nih.gov/37351564\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"Jastreboff et al., NEJM 2023\"}],\").\"]}],[\"$\",\"p\",\"1\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"That was Phase 2, designed mainly to figure out the right dose and confirm the drug actually works. Phase 3 extends the testing to larger groups, longer durations, and more diverse patient populations. The TRIUMPH-4 result of 28.7% at 68 weeks exceeded the Phase 2 result, suggesting the effect strengthens with longer treatment.\"]}],[\"$\",\"p\",\"2\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"A substudy within the Phase 2 trial also found that retatrutide reduced liver fat by up to 82% in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), formerly called fatty liver disease. That reduction occurred within 48 weeks and exceeded the results of any other drug tested for that condition (\",[\"$\",\"a\",\"325\",{\"href\":\"https://pubmed.ncbi.nlm.nih.gov/38587239\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"Sanyal et al., NEJM 2024\"}],\"). For a deeper look at the mechanism behind these results, see \",[\"$\",\"$L10\",\"457\",{\"href\":\"/blog/how-does-retatrutide-work\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"how does retatrutide work\"}],\".\"]}]]}]}]]}]\n"])

self.__next_f.push([1,"47:[\"$\",\"div\",\"2\",{\"className\":\"bg-[#F8F8F8] border-l-4 border-[#1526C9] p-5 rounded-r-xl\",\"children\":[[\"$\",\"h3\",null,{\"id\":\"step-3-fda-review-period-6-to-10-months\",\"className\":\"text-lg font-bold text-[#111] mb-2\",\"children\":\"Step 3: FDA Review Period (6 to 10 Months)\"}],[\"$\",\"div\",null,{\"className\":\"text-sm\",\"children\":[\"$\",\"div\",null,{\"className\":\"space-y-4\",\"children\":[[\"$\",\"p\",\"0\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Once the FDA accepts the NDA for review, it has 10 months for a Standard Review or 6 months for a Priority Review. Priority Review is granted when a drug represents a \\\"significant improvement\\\" over existing treatments.\"]}],[\"$\",\"p\",\"1\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Does retatrutide qualify for Priority Review? There is a strong argument that it does. No approved drug produces 28.7% weight loss. The closest, tirzepatide, peaks around 22.5%. That 6-percentage-point gap is clinically meaningful, representing an additional 15 to 20 pounds of weight loss for the average patient. The liver fat reduction data and potential cardiovascular benefits add further justification.\"]}],[\"$\",\"p\",\"2\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"However, the FDA has been cautious with weight loss drugs historically. The agency may want the full 10-month Standard Review to thoroughly examine the dysesthesia signal and the cardiovascular safety data from TRIUMPH-3. If TRIUMPH-3 is not complete by the time of submission, the FDA may require Lilly to submit that data as a post-marketing commitment, which would allow approval to proceed but with conditions.\"]}],[\"$\",\"div\",\"3\",{\"children\":[\"$\",\"div\",null,{\"className\":\"overflow-x-auto rounded-xl border border-gray-200\",\"children\":[\"$\",\"table\",null,{\"className\":\"w-full text-sm\",\"children\":[[\"$\",\"thead\",null,{\"children\":[\"$\",\"tr\",null,{\"className\":\"bg-[#F8F8F8]\",\"children\":[[\"$\",\"th\",\"0\",{\"className\":\"text-left text-[#111] font-semibold px-4 py-3 border-b border-gray-200\",\"children\":[\"Review Type\"]}],[\"$\",\"th\",\"1\",{\"className\":\"text-left text-[#111] font-semibold px-4 py-3 border-b border-gray-200\",\"children\":[\"Duration\"]}],[\"$\",\"th\",\"2\",{\"className\":\"text-left text-[#111] font-semibold px-4 py-3 border-b border-gray-200\",\"children\":[\"Likelihood for Retatrutide\"]}]]}]}],[\"$\",\"tbody\",null,{\"children\":[[\"$\",\"tr\",\"0\",{\"className\":\"\",\"children\":[[\"$\",\"td\",\"0\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Priority Review\"]}],[\"$\",\"td\",\"1\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"6 months\"]}],[\"$\",\"td\",\"2\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Possible (unprecedented weight loss)\"]}]]}],[\"$\",\"tr\",\"1\",{\"className\":\"bg-[#FAFAFA]\",\"children\":[[\"$\",\"td\",\"0\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Standard Review\"]}],[\"$\",\"td\",\"1\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"10 months\"]}],[\"$\",\"td\",\"2\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"More likely (cautious FDA approach)\"]}]]}]]}]]}]}]}],[\"$\",\"p\",\"4\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"If Lilly submits in Q4 2026 and receives Standard Review, the FDA decision would come around August to October 2027. With Priority Review, the decision could arrive as early as April to June 2027.\"]}]]}]}]]}]\n"])

self.__next_f.push([1,"48:[\"$\",\"div\",\"3\",{\"className\":\"bg-[#F8F8F8] border-l-4 border-[#1526C9] p-5 rounded-r-xl\",\"children\":[[\"$\",\"h3\",null,{\"id\":\"step-4-advisory-committee-meeting-if-needed\",\"className\":\"text-lg font-bold text-[#111] mb-2\",\"children\":\"Step 4: Advisory Committee Meeting (If Needed)\"}],[\"$\",\"div\",null,{\"className\":\"text-sm\",\"children\":[\"$\",\"div\",null,{\"className\":\"space-y-4\",\"children\":[[\"$\",\"p\",\"0\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"The FDA sometimes convenes an independent panel of outside experts, called an Advisory Committee, to publicly debate whether a drug should be approved. These meetings are not mandatory. The FDA skipped the advisory committee for tirzepatide's obesity indication (Zepbound) in 2023, approving it directly.\"]}],[\"$\",\"p\",\"1\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"For retatrutide, an advisory committee meeting is possible but not certain. The dysesthesia safety signal and the novel triple-agonist mechanism might prompt the FDA to seek external input. If scheduled, the meeting typically occurs 1 to 2 months before the approval decision date (called the PDUFA date). The committee's recommendation is non-binding but almost always followed.\"]}],[\"$\",\"p\",\"2\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Advisory committees rarely derail drugs that have strong efficacy data. The bigger risk is a \\\"complete response letter,\\\" where the FDA asks for additional data or changes before granting approval. This would push the timeline back by 6 to 12 months. Complete response letters have become uncommon for obesity drugs with large, well-run trial programs (\",[\"$\",\"a\",\"352\",{\"href\":\"https://www.fda.gov/about-fda/fda-organization/center-drug-evaluation-and-research-cder\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"FDA CDER\"}],\").\"]}]]}]}]]}]\n"])

self.__next_f.push([1,"49:[\"$\",\"div\",\"4\",{\"className\":\"bg-[#F8F8F8] border-l-4 border-[#1526C9] p-5 rounded-r-xl\",\"children\":[[\"$\",\"h3\",null,{\"id\":\"step-5-commercial-launch-late-2027-to-early-2028\",\"className\":\"text-lg font-bold text-[#111] mb-2\",\"children\":\"Step 5: Commercial Launch (Late 2027 to Early 2028)\"}],[\"$\",\"div\",null,{\"className\":\"text-sm\",\"children\":[\"$\",\"div\",null,{\"className\":\"space-y-4\",\"children\":[[\"$\",\"p\",\"0\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"FDA approval is not the same as pharmacy availability. After approval, Eli Lilly needs to manufacture enough supply, negotiate insurance coverage, set up distribution, and train healthcare providers on the new drug. Based on how Lilly launched Zepbound (tirzepatide for weight loss), this ramp-up takes 2 to 4 months.\"]}],[\"$\",\"p\",\"1\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Zepbound was approved on November 8, 2023, and was available at pharmacies within a few weeks. But it took months for insurance coverage to expand, and supply shortages persisted into 2024. Lilly has learned from that experience and is likely investing in manufacturing capacity for retatrutide well ahead of approval.\"]}],[\"$\",\"div\",\"2\",{\"children\":[\"$\",\"div\",null,{\"className\":\"overflow-x-auto rounded-xl border border-gray-200\",\"children\":[\"$\",\"table\",null,{\"className\":\"w-full text-sm\",\"children\":[[\"$\",\"thead\",null,{\"children\":[\"$\",\"tr\",null,{\"className\":\"bg-[#F8F8F8]\",\"children\":[[\"$\",\"th\",\"0\",{\"className\":\"text-left text-[#111] font-semibold px-4 py-3 border-b border-gray-200\",\"children\":[\"Milestone\"]}],[\"$\",\"th\",\"1\",{\"className\":\"text-left text-[#111] font-semibold px-4 py-3 border-b border-gray-200\",\"children\":[\"Best Case\"]}],[\"$\",\"th\",\"2\",{\"className\":\"text-left text-[#111] font-semibold px-4 py-3 border-b border-gray-200\",\"children\":[\"Most Likely\"]}]]}]}],[\"$\",\"tbody\",null,{\"children\":[[\"$\",\"tr\",\"0\",{\"className\":\"\",\"children\":[[\"$\",\"td\",\"0\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Pivotal trial results\"]}],[\"$\",\"td\",\"1\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Mid-2026\"]}],[\"$\",\"td\",\"2\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Mid-2026\"]}]]}],[\"$\",\"tr\",\"1\",{\"className\":\"bg-[#FAFAFA]\",\"children\":[[\"$\",\"td\",\"0\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"NDA submission\"]}],[\"$\",\"td\",\"1\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Q3 2026\"]}],[\"$\",\"td\",\"2\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Q4 2026\"]}]]}],[\"$\",\"tr\",\"2\",{\"className\":\"\",\"children\":[[\"$\",\"td\",\"0\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"FDA decision\"]}],[\"$\",\"td\",\"1\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Q2 2027\"]}],[\"$\",\"td\",\"2\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Q3-Q4 2027\"]}]]}],[\"$\",\"tr\",\"3\",{\"className\":\"bg-[#FAFAFA]\",\"children\":[[\"$\",\"td\",\"0\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"First prescriptions filled\"]}],[\"$\",\"td\",\"1\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Q3 2027\"]}],[\"$\",\"td\",\"2\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Q4 2027 to Q1 2028\"]}]]}],[\"$\",\"tr\",\"4\",{\"className\":\"\",\"children\":[[\"$\",\"td\",\"0\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Broad insurance coverage\"]}],[\"$\",\"td\",\"1\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Q4 2027\"]}],[\"$\",\"td\",\"2\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Mid-2028\"]}]]}]]}]]}]}]}],[\"$\",\"p\",\"3\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"The cost at launch will likely mirror Zepbound's pricing: approximately $1,000 to $1,100 per month before insurance. Eli Lilly typically offers manufacturer savings cards that can reduce the out-of-pocket cost to $25 per month for eligible patients. Use our \",\"$L6a\",\" to compare current options. For details on insurance dynamics, see \",\"$L6b\",\".\"]}]]}]}]]}]\n"])

self.__next_f.push([1,"4a:[\"$\",\"td\",\"1\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Late 2023\"]}]\n4b:[\"$\",\"p\",\"3\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"For a look at semaglutide results, see \",[\"$\",\"$L10\",\"39\",{\"href\":\"/blog/semaglutide-before-and-after\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"semaglutide before and after\"}],\".\"]}]\n"])

self.__next_f.push([1,"4c:[\"$\",\"div\",\"1\",{\"className\":\"bg-[#F8F8F8] border-l-4 border-[#1526C9] p-5 rounded-r-xl\",\"children\":[[\"$\",\"h3\",null,{\"id\":\"tirzepatide-from-phase-3-to-pharmacy-in-2-5-years\",\"className\":\"text-lg font-bold text-[#111] mb-2\",\"children\":\"Tirzepatide: From Phase 3 to Pharmacy in 2.5 Years\"}],[\"$\",\"div\",null,{\"className\":\"text-sm\",\"children\":[\"$\",\"div\",null,{\"className\":\"space-y-4\",\"children\":[[\"$\",\"p\",\"0\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Eli Lilly started the SURMOUNT trial program for tirzepatide in late 2020. SURMOUNT-1 published in the New England Journal of Medicine in July 2022, showing 22.5% weight loss at 72 weeks (\",[\"$\",\"a\",\"188\",{\"href\":\"https://pubmed.ncbi.nlm.nih.gov/35658024\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"Jastreboff et al., NEJM 2022\"}],\").\"]}],[\"$\",\"p\",\"1\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Lilly submitted the NDA for Zepbound in mid-2023 and received FDA approval on November 8, 2023. Total time from first Phase 3 enrollment to approval: roughly 3 years. Unlike semaglutide, Zepbound was available at pharmacies within weeks of approval, though supply constraints persisted for months.\"]}],[\"$\",\"div\",\"2\",{\"children\":[\"$\",\"div\",null,{\"className\":\"overflow-x-auto rounded-xl border border-gray-200\",\"children\":[\"$\",\"table\",null,{\"className\":\"w-full text-sm\",\"children\":[[\"$\",\"thead\",null,{\"children\":[\"$\",\"tr\",null,{\"className\":\"bg-[#F8F8F8]\",\"children\":[[\"$\",\"th\",\"0\",{\"className\":\"text-left text-[#111] font-semibold px-4 py-3 border-b border-gray-200\",\"children\":[\"Tirzepatide (Zepbound)\"]}],[\"$\",\"th\",\"1\",{\"className\":\"text-left text-[#111] font-semibold px-4 py-3 border-b border-gray-200\",\"children\":[\"Date\"]}]]}]}],[\"$\",\"tbody\",null,{\"children\":[[\"$\",\"tr\",\"0\",{\"className\":\"\",\"children\":[[\"$\",\"td\",\"0\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"SURMOUNT-1 trial start\"]}],[\"$\",\"td\",\"1\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Late 2020\"]}]]}],[\"$\",\"tr\",\"1\",{\"className\":\"bg-[#FAFAFA]\",\"children\":[[\"$\",\"td\",\"0\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"SURMOUNT-1 results\"]}],[\"$\",\"td\",\"1\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"July 2022\"]}]]}],[\"$\",\"tr\",\"2\",{\"className\":\"\",\"children\":[[\"$\",\"td\",\"0\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"NDA submission\"]}],[\"$\",\"td\",\"1\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Mid-2023\"]}]]}],[\"$\",\"tr\",\"3\",{\"className\":\"bg-[#FAFAFA]\",\"children\":[[\"$\",\"td\",\"0\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"FDA approval\"]}],[\"$\",\"td\",\"1\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"November 2023\"]}]]}],[\"$\",\"tr\",\"4\",{\"className\":\"\",\"children\":[[\"$\",\"td\",\"0\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Pharmacy availability\"]}],[\"$\",\"td\",\"1\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"December 2023\"]}]]}]]}]]}]}]}],[\"$\",\"p\",\"3\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"For dosing guidance on tirzepatide, see \",[\"$\",\"$L10\",\"40\",{\"href\":\"/blog/how-long-does-tirzepatide-take-to-work\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"how long does tirzepatide take to work\"}],\".\"]}]]}]}]]}]\n"])

self.__next_f.push([1,"4d:[\"$\",\"div\",\"2\",{\"className\":\"bg-[#F8F8F8] border-l-4 border-[#1526C9] p-5 rounded-r-xl\",\"children\":[[\"$\",\"h3\",null,{\"id\":\"what-this-tells-us-about-retatrutide\",\"className\":\"text-lg font-bold text-[#111] mb-2\",\"children\":\"What This Tells Us About Retatrutide\"}],[\"$\",\"div\",null,{\"className\":\"text-sm\",\"children\":[\"$\",\"div\",null,{\"className\":\"space-y-4\",\"children\":[[\"$\",\"p\",\"0\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Both semaglutide and tirzepatide took approximately 3 years from first Phase 3 enrollment to FDA approval. The TRIUMPH program began enrolling in mid-2023. Applying the same 3-year window points to mid-2026 at the earliest and mid-2027 as the more realistic target.\"]}],[\"$\",\"p\",\"1\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Lilly has one advantage this time: institutional experience. The company navigated the tirzepatide approval process just two years ago. The regulatory team, manufacturing infrastructure, and commercial playbook are already in place. This could shave a few months off the timeline, particularly in the NDA preparation and launch phases.\"]}],[\"$\",\"p\",\"2\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"The potential delay factor is the triple-agonist novelty. Semaglutide and tirzepatide had predecessor drugs in their same class that the FDA had already reviewed (liraglutide and native GIP, respectively). Retatrutide's glucagon component is new territory for the agency. The FDA may take extra time to evaluate the glucagon-related safety signals, particularly the heart rate increase (up to 6.7 bpm above baseline) and dysesthesia (\",[\"$\",\"a\",\"434\",{\"href\":\"https://pubmed.ncbi.nlm.nih.gov/38858523\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"Nature Medicine, 2024\"}],\").\"]}]]}]}]]}]\n"])

self.__next_f.push([1,"4e:[\"$\",\"a\",\"542\",{\"href\":\"https://pubmed.ncbi.nlm.nih.gov/36424368\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"Coskun et al., Nature 2022\"}]\n4f:[\"$\",\"p\",\"2\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"The FDA will want long-term cardiovascular data to confirm that the heart rate increase does not translate into higher rates of heart attacks or strokes. TRIUMPH-3 (the cardiovascular outcomes trial with 1,800 patients) is designed to answer exactly this question. For a comparison of \",[\"$\",\"$L10\",\"285\",{\"href\":\"/blog/retatrutide-vs-tirzepatide\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"retatrutide vs tirzepatide\"}],\" including safety profiles, see our dedicated analysis.\"]}]\n"])

self.__next_f.push([1,"50:[\"$\",\"div\",\"2\",{\"className\":\"bg-[#F8F8F8] border-l-4 border-[#1526C9] p-5 rounded-r-xl\",\"children\":[[\"$\",\"h3\",null,{\"id\":\"manufacturing-a-novel-peptide-at-scale\",\"className\":\"text-lg font-bold text-[#111] mb-2\",\"children\":\"Manufacturing a Novel Peptide at Scale\"}],[\"$\",\"div\",null,{\"className\":\"text-sm\",\"children\":[\"$\",\"div\",null,{\"className\":\"space-y-4\",\"children\":[[\"$\",\"p\",\"0\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Retatrutide is a 39-amino-acid synthetic peptide with a fatty acid modification that extends its half-life. Manufacturing peptides at pharmaceutical scale is technically challenging. Each amino acid must be added in precise sequence, the fatty acid must be attached at the correct position, and the final product must be purified to greater than 99% purity (\",[\"$\",\"a\",\"358\",{\"href\":\"https://pubmed.ncbi.nlm.nih.gov/29066043\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"Lau \u0026 Dunn, Bioorganic \u0026 Medicinal Chemistry 2018\"}],\").\"]}],[\"$\",\"p\",\"1\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Eli Lilly invested $4 billion in expanding its manufacturing facilities in 2024 and 2025, partly in anticipation of retatrutide demand. The company opened a new facility in Lebanon, Indiana, and expanded its Research Triangle Park site in North Carolina. These investments suggest Lilly is confident in approval and is building capacity ahead of it.\"]}],[\"$\",\"p\",\"2\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Manufacturing bottlenecks delayed semaglutide (Wegovy) availability for over two years after approval. Lilly appears determined to avoid repeating that mistake with retatrutide. For context on current peptide sourcing, see \",[\"$\",\"$L10\",\"223\",{\"href\":\"/blog/where-to-buy-peptides-2026\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"where to buy peptides in 2026\"}],\" and \",[\"$\",\"$L10\",\"293\",{\"href\":\"/blog/peptide-sciences-alternatives\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"peptide sciences alternatives\"}],\".\"]}]]}]}]]}]\n"])

self.__next_f.push([1,"51:[\"$\",\"div\",\"2\",{\"className\":\"bg-[#F8F8F8] border-l-4 border-[#1526C9] p-5 rounded-r-xl\",\"children\":[[\"$\",\"h3\",null,{\"id\":\"research-peptides-the-gray-market-risks-apply\",\"className\":\"text-lg font-bold text-[#111] mb-2\",\"children\":\"Research Peptides: The Gray Market (Risks Apply)\"}],[\"$\",\"div\",null,{\"className\":\"text-sm\",\"children\":[\"$\",\"div\",null,{\"className\":\"space-y-4\",\"children\":[[\"$\",\"p\",\"0\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Some online vendors sell retatrutide labeled \\\"for research use only, not for human consumption.\\\" These products are not manufactured to pharmaceutical standards, are not inspected by the FDA, and their purity varies widely between suppliers.\"]}],[\"$\",\"p\",\"1\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"The FDA has taken aggressive enforcement action against peptide vendors since 2024. Over 50 warning letters were issued to GLP-1 compounders in September 2025 alone. Peptide Sciences, one of the largest research vendors, shut down voluntarily in early 2026. The legal and safety landscape for research peptides is increasingly hostile. For the full regulatory picture, see \",[\"$\",\"$L10\",\"373\",{\"href\":\"/blog/fda-peptide-crackdown-2026\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"FDA peptide crackdown 2026\"}],\".\"]}],[\"$\",\"p\",\"2\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"If you choose to go this route, understand the quantified risks. A 2024 FDA investigation of seized GLP-1 peptide samples found that 15% contained bacterial endotoxins exceeding safety limits. Another 8% had purity below 90%, meaning up to 10% of the vial contained unknown impurities. Some samples contained heavy metals including lead and cadmium at levels exceeding USP limits (\",[\"$\",\"a\",\"381\",{\"href\":\"https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"FDA Safety Communication, 2025\"}],\"). For general safety guidance, see our \",[\"$\",\"$L10\",\"592\",{\"href\":\"/blog/peptide-safety-guide\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"peptide safety guide\"}],\".\"]}]]}]}]]}]\n"])

self.__next_f.push([1,"52:[\"$\",\"td\",\"2\",{\"className\":\"text-[#666] px-4 py-3 border-b border-gray-100\",\"children\":[\"Eli Lilly\"]}]\n53:[\"$\",\"p\",\"3\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Use the \",[\"$\",\"$L10\",\"8\",{\"href\":\"/tools/peptide-cost-calculator\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"peptide cost calculator\"}],\" to compare costs across available options.\"]}]\n"])

self.__next_f.push([1,"54:[\"$\",\"div\",\"1\",{\"className\":\"bg-[#F8F8F8] border-l-4 border-[#1526C9] p-5 rounded-r-xl\",\"children\":[[\"$\",\"h3\",null,{\"id\":\"insurance-coverage-expectations\",\"className\":\"text-lg font-bold text-[#111] mb-2\",\"children\":\"Insurance Coverage Expectations\"}],[\"$\",\"div\",null,{\"className\":\"text-sm\",\"children\":[\"$\",\"div\",null,{\"className\":\"space-y-4\",\"children\":[[\"$\",\"p\",\"0\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Insurance coverage for weight loss drugs remains inconsistent. As of early 2026, most commercial insurance plans cover Mounjaro (diabetes indication) but fewer cover Zepbound (weight loss indication). Medicare does not cover any weight loss drugs.\"]}],[\"$\",\"p\",\"1\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Legislation is moving in the right direction. The Treat and Reduce Obesity Act has been reintroduced in Congress multiple times, and some state Medicaid programs have begun covering GLP-1 agonists for obesity. By the time retatrutide reaches market in late 2027 or 2028, coverage may have expanded significantly.\"]}],[\"$\",\"p\",\"2\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Eli Lilly will almost certainly offer a manufacturer savings card for retatrutide, similar to the Zepbound savings card that reduces the monthly cost to $25 for commercially insured patients. These programs typically exclude government insurance (Medicare, Medicaid, Tricare). For a breakdown of current insurance dynamics, see \",[\"$\",\"$L10\",\"328\",{\"href\":\"/blog/tirzepatide-cost-with-insurance\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"tirzepatide cost with insurance\"}],\".\"]}]]}]}]]}]\n"])

self.__next_f.push([1,"55:[\"$\",\"div\",\"2\",{\"className\":\"bg-[#F8F8F8] border-l-4 border-[#1526C9] p-5 rounded-r-xl\",\"children\":[[\"$\",\"h3\",null,{\"id\":\"will-compounding-pharmacies-make-generic-retatrutide\",\"className\":\"text-lg font-bold text-[#111] mb-2\",\"children\":\"Will Compounding Pharmacies Make Generic Retatrutide?\"}],[\"$\",\"div\",null,{\"className\":\"text-sm\",\"children\":[\"$\",\"div\",null,{\"className\":\"space-y-4\",\"children\":[[\"$\",\"p\",\"0\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Not legally. US law only permits compounding of drugs that are already FDA-approved and either on the drug shortage list or not commercially available in a needed form. Retatrutide has never been approved, so there is no legal basis for compounding it.\"]}],[\"$\",\"p\",\"1\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Even after approval, compounding would only be permitted if retatrutide entered the FDA's drug shortage list, which happened with both semaglutide and tirzepatide. Lilly's manufacturing investments suggest the company is trying to avoid shortage scenarios. For background on the compounding landscape, see \",[\"$\",\"$L10\",\"306\",{\"href\":\"/blog/is-compound-tirzepatide-safe\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"is compound tirzepatide safe\"}],\" and \",[\"$\",\"$L10\",\"377\",{\"href\":\"/blog/compound-semaglutide-with-b12\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"compound semaglutide with B12\"}],\".\"]}],[\"$\",\"p\",\"2\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"True generic competition is even further away. Eli Lilly's patents on retatrutide extend into the 2040s. A generic version would require those patents to expire or be successfully challenged, plus a separate FDA approval process for the generic. You should not expect a generic retatrutide for at least 15 years after initial approval.\"]}]]}]}]]}]\n"])

self.__next_f.push([1,"56:[\"$\",\"div\",\"2\",{\"className\":\"bg-[#F8F8F8] border-l-4 border-[#1526C9] p-5 rounded-r-xl\",\"children\":[[\"$\",\"h3\",null,{\"id\":\"build-the-foundation-that-amplifies-results\",\"className\":\"text-lg font-bold text-[#111] mb-2\",\"children\":\"Build the Foundation That Amplifies Results\"}],[\"$\",\"div\",null,{\"className\":\"text-sm\",\"children\":[\"$\",\"div\",null,{\"className\":\"space-y-4\",\"children\":[[\"$\",\"p\",\"0\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Weight loss drugs produce better outcomes when combined with behavioral changes. Clinical trials require participants to follow a reduced-calorie diet and increase physical activity, and the weight loss numbers reflect that combination. The drug alone produces less.\"]}],[\"$\",\"p\",\"1\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Start tracking measurable health markers now: weight, waist circumference, blood pressure, fasting blood sugar, and cholesterol. This creates a baseline so you can accurately measure the impact of any treatment you eventually start. It also documents your weight management efforts, which insurance companies and clinical trials look for.\"]}],[\"$\",\"p\",\"2\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"For broader guidance on beginning a peptide-based protocol, see \",[\"$\",\"$L10\",\"64\",{\"href\":\"/blog/getting-started-with-peptides\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"getting started with peptides\"}],\". For preparation and storage fundamentals, see \",[\"$\",\"$L10\",\"180\",{\"href\":\"/blog/how-to-store-peptides\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"how to store peptides\"}],\" and \",[\"$\",\"$L10\",\"237\",{\"href\":\"/blog/how-to-reconstitute-retatrutide\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"how to reconstitute retatrutide\"}],\".\"]}]]}]}]]}]\n"])

self.__next_f.push([1,"57:[\"$\",\"p\",\"3\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[[\"$\",\"strong\",\"0\",{\"className\":\"text-[#111] font-semibold\",\"children\":[\"Complete response letter.\"]}],\" If the FDA issues a complete response letter (asking for more data rather than approving), the delay is typically 6 to 12 months. This happened to lorcaserin (Belviq) and naltrexone/bupropion (Contrave) before their eventual approvals.\"]}]\n58:[\"$\",\"$L10\",\"65\",{\"href\":\"/blog/fda-peptide-crackdown-2026\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"FDA peptide crackdown 2026\"}]\n59:[\"$\",\"$L10\",\"185\",{\"href\":\"/blog/peptide-dosage-chart\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"peptide dosage chart\"}]\n5a:[\"$\",\"$L10\",\"274\",{\"href\":\"/tools/peptide-reconstitution-calculator\",\"className\":\"text-[#1526C9] hover:underline font-medium\",\"children\":\"peptide reconstitution calculator\"}]\n5b:[\"$\",\"div\",null,{\"className\":\"space-y-4 mt-4\",\"children\":[]}]\n5c:[\"$\",\"span\",null,{\"className\":\"text-[#111] font-semibold text-sm pr-4\",\"children\":\"Can I buy retatrutide online right now?\"}]\n5d:[\"$\",\"svg\",null,{\"className\":\"w-5 h-5 text-[#999] flex-shrink-0 transition-transform group-open:rotate-180\",\"fill\":\"none\",\"viewBox\":\"0 0 24 24\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"children\":[\"$\",\"path\",null,{\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"d\":\"M19 9l-7 7-7-7\"}]}]\n5e:[\"$\",\"div\",null,{\"className\":\"px-5 pb-5 -mt-1 text-sm\",\"children\":[\"$\",\"div\",null,{\"className\":\"space-y-4\",\"children\":[[\"$\",\"p\",\"0\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Some vendors sell retatrutide labeled 'for research use only.' These products are not manufactured to pharmaceutical standards and are not regulated by the FDA. Testing of seized samples has found bacterial endotoxins, heavy metals, and purity levels below 90%. The FDA has issued dozens of warning letters to peptide vendors since 2024.\"]}]]}]}]\n5f:[\"$\",\"details\",\"4\",{\"className\":\"group bg-[#F8F8F8] border border-gray-200 rounded-2xl overflow-hidden\",\"children\":[[\"$\",\"summary\",null,{\"className\":\"flex items-center justify-between p-5 cursor-pointer list-none\",\"children\":[[\"$\",\"span\",null,{\"className\":\"text-[#111] font-semibold text-sm pr-4\",\"children\":\"How does retatrutide compare to tirzepatide and semaglutide?\"}],[\"$\",\"svg\",null,{\"className\":\"w-5 h-5 text-[#999] flex-shrink-0 transition-transform group-open:rotate-180\",\"fill\":\"none\",\"viewBox\":\"0 0 24 24\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"children\":[\"$\",\"path\",null,{\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"d\":\"M19 9l-7 7-7-7\"}]}]]}],[\"$\",\"div\",null,{\"className\":\"px-5 pb-5 -mt-1 text-sm\",\"children\":[\"$\",\"div\",null,{\"className\":\"space-y-4\",\"children\":[[\"$\",\"p\",\"0\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Retatrutide targets three receptors (GLP-1, GIP, glucagon) and produced 28.7% weight loss. Tirzepatide targets two receptors (GLP-1, GIP) and produced 22.5% weight loss. Semaglutide targets one receptor (GLP-1) and produced 15% weight loss. More receptors means more weight loss but also more side effects. Tirzepatide and semaglutide are available now. Retatrutide is not.\"]}]]}]}]]}]\n60:[\"$\",\"details\",\"5\",{\"className\":\"group bg-[#F8F8F8] border border-gray-200 rounded-2xl overflow-hidden\",\"children\":[[\"$\",\"summary\",null,{\"className\":\"flex items-center justify-between p-5 cursor-pointer list-none\",\"children\":[[\"$\",\"span\",null,{\"className\":\"text-[#111] font-semibold text-sm pr-4\",\"children\":\"Will insurance cover retatrutide?\"}],[\"$\",\"svg\",null,{\"className\":\"w-5 h-5 text-[#999] flex-shrink-0 transition-transform group-open:rotate-180\",\"fill\":\"none\",\"viewBox\":\"0 0 24 24\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"children\":[\"$\",\"path\",null,{\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"d\":\"M19 9l-7 7-7-7\"}]}]]}],[\"$\",\"div\",null,{\"className\":\"px-5 pb-5 -mt-1 text-sm\",\"children\":[\"$\",\"div\",null,{\"className\":\"space-y-4\",\"children\":[[\"$\",\"p\",\"0\",{\"className\":\"text-[#666] leading-relaxed\",\"children\":[\"Unknown, but expectations are mixed. Coverage for weight loss drugs remains inconsistent across insur"])

Requests	IP Address	Location	AS Autonomous System
21	142.251.110.97Google · CDN	United States	AS15169Google LLC
20	76.76.21.21	Walnut, California, United States	AS16509Amazon.com, Inc.
20	104.26.0.192Cloudflare · WAF	United States	AS13335Cloudflare, Inc.
61	3	-	-

Security Scan Report: peptidesexplorer.com

Summary

AI Security Verdict

Low Risk

Risk Factors

Safety Factors

Details

Screenshot

Page Load Overview

Language Analysis

Primary Language

Detection Details

Website Classification

Primary Category

All Detected Categories

Detected Features

Domain & IP Information

Detected Technologies4

Content Similarity HashesFor malware variant detection

TLSH (Trend Micro Locality Sensitive Hash)

ssdeep (Context Triggered Piecewise Hashing)

sdhash (Similarity Digest Hashing)

Image Hashes

Perceptual Hashes

Other Hashes

Scan History